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LONGITUDINAL BRAIN TUMOR TRACKING, TUMOR GRADING, AND 
PATIENT SURVIVAL PREDICTION USING MRI  
 
Linmin Pei 
Old Dominion University, 2020 
Director: Dr. Khan M. Iftekharuddin 
This work aims to develop novel methods for brain tumor classification, longitudinal 
brain tumor tracking, and patient survival prediction. Consequently, this dissertation 
proposes three tasks. First, we develop a framework for brain tumor segmentation 
prediction in longitudinal multimodal magnetic resonance imaging (mMRI) scans, 
comprising two methods: feature fusion and joint label fusion (JLF). The first method 
fuses stochastic multi-resolution texture features with tumor cell density features, in order 
to obtain tumor segmentation predictions in follow-up scans from a baseline pre-
operative timepoint. The second method utilizes JLF to combine segmentation labels 
obtained from (i) the stochastic texture feature-based and Random Forest (RF)-based 
tumor segmentation method; and (ii) another state-of-the-art tumor growth and 
segmentation method known as boosted Glioma Image Segmentation and Registration 
(GLISTRboost, or GB). With the advantages of feature fusion and label fusion, we 
achieve state-of-the-art brain tumor segmentation prediction. 
Second, we propose a deep neural network (DNN) learning-based method for brain 
tumor type and subtype grading using phenotypic and genotypic data, following the 
World Health Organization (WHO) criteria. In addition, the classification method 
integrates a cellularity feature which is derived from the morphology of a pathology 
   
 
iii 
image to improve classification performance. The proposed method achieves state-of-the-
art performance for tumor grading following the new CNS tumor grading criteria.  
Finally, we investigate brain tumor volume segmentation, tumor subtype 
classification, and overall patient survival prediction, and then we propose a new context- 
aware deep learning method, known as the Context Aware Convolutional Neural 
Network (CANet). Using the proposed method, we participated in the Multimodal Brain 
Tumor Segmentation Challenge 2019 (BraTS 2019) for brain tumor volume segmentation 
and overall survival prediction tasks. In addition, we also participated in the Radiology-
Pathology Challenge 2019 (CPM-RadPath 2019) for Brain Tumor Subtype Classification, 
organized by the Medical Image Computing & Computer Assisted Intervention 
(MICCAI) Society. The online evaluation results show that the proposed methods offer 
competitive performance from their use of state-of-the-art methods in tumor volume 
segmentation, promising performance on overall survival prediction, and state-of-the-art 
performance on tumor subtype classification. Moreover, our result was ranked second 
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Gliomas in central nervous system (CNS), the most common primary brain 
malignancies, originate from glial cells in the brain [1].  In the US, 23 out of 100,000 in 
the population have been reported as patients with brain tumors annually, from 2011-
2015 [2].  According to the report, 392,982 cases consisted of 30.9% patients with 
malignant tumors and 69.1% patients with non-malignant tumors [2], as shown in Figure 
1. 
Prior to 2016, a brain tumor may have been graded as I, II, III, and IV respectively, 
based on the growth rate, the presence of definitive tumor margins, and the vascularity, 
according to the World Health Organization (WHO)’s 2007 diagnostic schema [3]. In 
2016, WHO adapted to a new tumor classification criterion based on both phenotype and 
genotype [4]. In general, a patient’s survival period is associated with the tumor grade. 
The survival period of a patient with a low-grade tumor is much longer than that of a 
Figure 1. Distribution of primary brain and other CNS tumors reported during 
2011-2015 [1]. 
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patient with a high-grade tumor. According to the report, from 2011-2015, for patients 
with malignant tumors, the estimated five- and ten- year relative survival rates were 
35.0% and 29.3%, respectively [2]. Glioblastoma multiforme (GBM), originating from 
glial cells and growing by infiltrating surround tissues, is the most common and a highly 
aggressive type of glioma. The median of the survival period for a patient with GBM still 
remains at 12-16 months, even though there have been many treatment advancements [5]. 
Less than 4% of treated patients with GBM are alive after five years [5-7]. The short 
survival period of patients with GBM is not only because of the rapid tumor growth, but 
is also due to the tumor’s invasion to surrounding brain tissues [8]. Early and proper 
detection of the tumor grade may result in a good prognosis [9]. 
To achieve a proper prognosis, treatment planning, and follow-up to the patients, 
accurate detection, and segmentation of brain tumor are critical. Manual tumor 
segmentation by radiologists is very tedious, time consuming, and prone to human error 
[10]. Consequently, computer-aided brain tumor analysis is desired. In a clinic, several 
image modalities are used for tumor diagnosis, such as computerized tomography (CT), 
magnetic resonance imaging (MRI), digital pathology image (DPI), etc. CT is used for 
brain tumor detection in its early stages [11]. In its later stages, a structural MRI is widely 
used for brain tumor analysis, especially for tumor detection and segmentation [1, 12-17]. 
In the literature, many methods have been proposed to detect and segment brain tumors, 
such as the active contours-based and atlas-based methods. However, performances of 
tumor segmentation using atlas-based methods are suffering from the quality of their 
image registration. To overcome this issue, brain tumor segmentation is treated as a 
classification problem. Traditional machine learning classifiers, such as K-nearest 
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neighbor (KNN), support vector machine (SVM), and random forest (RF), are generally 
used. As we know, effective and robust feature extraction is the prerequisite for 
traditional machine learning based brain tumor segmentation methods. In recent years, 
with the success of deep learning in many fields, such as computer vision, speech 
recognition, etc., deep learning-based methods have also been applied to medical imaging 
processing, including brain tumor detection, segmentation, grading, etc.  
Diffuse low-grade gliomas (LGG) and intermediate-grade gliomas are infiltrative 
brain neoplasms which include the histological classes Astrocytoma, 
Oligodendrogliomas, Oligoastrocytomas, and World Health Organization (WHO) grade 
II and III neoplasms. High-grade gliomas are mainly Glioblastoma (WHO grade IV). 
Although LGG patients have a longer survival period than those with HGG, the LGGs 
have been found to typically progress to secondary GBMs with time, and they cause 
eventual death [9]. Tracking longitudinal brain tumor changes over time is critical for 
treatment management. Tracking is not only related to accurate tumor volume 
segmentation, but it also reveals information about tumor development over time. 
Moreover, similar to brain tumor classification, tumor tracking may be useful for patient 
survival prediction. Finally, even though there are a few studies on longitudinal brain 
tumor tracking in the literature, there is still a lack of robust methods.   
This dissertation proposes a novel framework for longitudinal brain tracking, a new 
tumor grading following the new WHO tumor classification criterion, and a robust deep 
learning architecture for brain tumor segmentation, tumor subtype classification, and 
overall patient survival prediction. 
1.1 Problem Statement 
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The topics mentioned above require efficient commuter-aided brain tumor analysis 
and abnormal tumor tissue segmentation methods. Even though there has been a plethora 
of techniques on brain tumor analysis and segmentation proposed in the literature, 
computer-aided brain tumor analysis is still a challenging task due to multiple factors. 
First, brain tumors can have an unpredictable appearance, infiltration to surrounding 
tissue, intensity heterogeneity, size, shape, and location variation [18]. Second, tumors 
have different degrees of aggressiveness, variable prognosis, and various heterogeneous 
histology [1]. Third, intensity gradients between adjacent structures can be obscured due 
to tumor penetration or bias field artifacts [12]. Lastly, MR images may be acquired 
following different protocols in clinical trials [19].  
Among the brain tumor analysis tasks, accurate tumor detection and volume 
segmentation are very important for tumor assessment and prognosis. The brain tumor 
analysis methods are generally categorized in two groups: traditional feature-based 
machine learning methods (such as K-nearest neighbors [20], support vector machine 
[21], random forest [22], etc.) and more recent deep neural network-based methods. For 
traditional machine learning-based methods, feature extraction is a challenging task. 
In general, LGGs are found to typically progress to HGGs, and to eventual death [9]. 
Longitudinal brain tumor tracking may be accomplished in at least two ways: a) via 
image-based tumor volume segmentation, and b) via computational modeling for tumor 
growth. As mentioned before, image-based tumor volume segmentation remains 
challenging because of imaging artifacts, the variety of image acquisition protocol, and 
tumor complex characteristics. Computational tumor growth modeling may be 
categorized as a microscopic model or a macroscopic model, according to the observation 
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scale. The macroscopic model, which refers to the reaction-diffusion formalism, is widely 
used in studies in the literature, because this model considers both microscopic 
proliferation and macroscopic diffusion. Tumor growth modeling is difficult because of 
two reasons: a) mass effect happens when the tumors invade and push the surrounding 
tumor [23, 24], and b) tumors grow at different rates in different types of brain tissues. 
For example, tumors have a faster growth rate in white matter (WM) than in gray matter 
(GM) [25]. 
As mentioned in the previous section, the WHO CNS tumor classification guideline 
changed in 2016. Prior to 2016, tumor classification was mainly based on histologic 
appearance in pathologic slides [3]. Specifically, tumors were classified according to 
microscopic similarities with different putative cells of origin and differentiation level 
[4]. The histological features of mitotic activity, microvascular proliferation, and necrosis 
are used when grading diffuse glioma. However, since using only histopathology data for 
tumor grading is no longer accurate and efficient, a new CNS brain tumor grade 
classification standard was released by the WHO in 2016 [4]. The new tumor 
classification standard requires both phenotype and proteomics information. The most 
common proteomics information has isocitrate dehydrogenase (IDH), X1p/19q 
codeletion, Alpha thalassemia/mental retardation syndrome X-linked (ATRX), and O6-
methylguanine-DNA methyl-transferase (MGMT). Since the new tumor classification 
criteria were released, there have been few studies in the literature that follow the revised 
tumor grading guidelines. 
Recently, deep learning methods have attracted huge attention because of the success 
in computer vision, pattern recognition, speech recognition, and medical imaging 
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processing. Although deep learning-based methods for brain tumor analysis have been an 
active area of research in recent years, relevant tasks, such as tumor segmentation, 
classification, and overall survival prediction, have mostly been studied individually, 
ignoring the underlying relationship among these critical analysis tasks. There is a need 
for developing deep learning methods that consider tumor segmentation, tumor subtype 
classification, and patient survival prediction as interdependent tasks. Consequently, the 
overall aim of this dissertation is to develop a longitudinal brain tumor tracking model 
that will help brain tumor diagnosis and classification, as well as patient survivability 
prediction. 
1.2 Proposed Work and Contributions 
This dissertation proposes novel methods for longitudinal brain tumor volume 
segmentation and tracking using multimodal MRI, a tumor subtype grading that uses a 
deep learning-based method, and tumor classification and survival prediction that uses a 
deep learning Context Aware-based Convolutional Neural Network (CANet). It follows 
the new WHO tumor classification guideline using structural MRI, and patient survival 
prediction is completed by using both structural MRI and clinical data. Consequently, our 
first dissertation goal is to improve longitudinal brain tumor tracking by integrating tumor 
segmentation and tumor growth modeling using multimodal magnetic resonance imaging 
(mMRI) scans. This comprises two methods: feature fusion and joint label fusion (JLF). 
The first method fuses stochastic multi-resolution texture features with tumor cell density 
features to obtain tumor segmentation predictions in follow-up timepoints, using data 
from a baseline pre-operative timepoint. The second method utilizes JLF to combine 
segmentation labels obtained from (i) the stochastic texture feature-based and the 
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Random Forest (RF)-based tumor segmentation method and (ii) another state-of-the-art 
tumor growth and segmentation method, known as boosted Glioma Image 
Segmentation and Registration (GLISTRboost, or GB).  
The overall novelty of this work is two-fold: a) tumor cell density is used as a novel 
feature to obtain tumor growth segmentation prediction for a prior successful stochastic 
multiresolution RF-based segmentation method, and b) it obtains improved tumor 
segmentation performance of another successful tumor segmentation tool, GB, by fusing 
labels obtained from the tumor segmentation using a RF-based method. 
The second goal of the dissertation is to perform brain tumor grading by analyzing 
phenotype and proteomics information, using deep learning. This dissertation proposes a 
joint analysis of histopathology and proteomics patient data using DNN for brain tumor 
grade type and subtype classification, following the new WHO tumor grade criteria. The 
work utilizes digital pathology images and four pieces of proteomics information (IDH, 
X1p/19q, ATRX, and MGMT) to obtain improved tumor classification accuracy. The 
contribution has two parts: 1) development of a deep learning-based method for tumor 
grading by utilizing phenotype and proteomics information, and 2) integration of 
cellularity obtained from digital pathology image (DPI) to improve tumor grading 
accuracy.  
Our final goal in this study is to build a robust deep learning architecture suitable for 
multiple tumor analysis tasks, including brain tumor segmentation, tumor subtype 
classification, and overall survival prediction. This dissertation proposes a context-aware 
deep learning method known as the Context Aware Neural Network (CANet). We offer 
three contributions, as follows: First, we propose a context-aware deep learning-based 
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method for brain tumor segmentation. Second, we utilize a hybrid method for overall 
survival prediction, which integrates the deep learning and traditional machine learning 
methods. Finally, although the new WHO tumor classification criteria indicate the use of 
both pathology images and proteomics information along with MRI, the proposed method 
is effective in tumor classification using structural MRI data only. A summary of the 
dissertation goals and contributions is listed in Table 1. 
We have several peer reviewed publications resulting from the dissertation 
contributions, as follow: The research finding related to Dissertation Goal 1 is published 
in the 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 
[15], Conference of Medical Imaging 2017: Computer-Aided Diagnosis [14], and Journal 
of Biomedical Signal Processing and Control (BSPC) [13]. The research findings related 
to Dissertation Goal 2 are under review by the Journal of Medical Image Analysis (MIA). 
Finally, the overall contributions of the Dissertation Goal 3 result were accepted as a 
conference paper in the Society of Photo-Optical Instrumentation Engineers (SPIE) 
Medical Imaging, and an expanded version of this Goal 3 is currently under review by the 
journal Scientific Reports – Nature. Moreover, we participated the Computational 
Precision Medicine: Radiology-Pathology Challenge on Brain Tumor Classification 2019 
(CPM-RadPath) [26], also known as National Institute Health (NIH) Computational 
Precision Medicine 2019 Challenge, for the proposed methods of our Dissertation Goal 3. 
Our result is ranked in second place in the testing phase [27].  
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Table 1. Summary of proposed contribution in the dissertation. 
 
1.3 Organization of the Dissertation 
The rest of the dissertation is organized as follows. Chapter 2 describes the 
background information of the overall dissertation, mainly including brain tumor in CNS, 
brain tumor segmentation, longitudinal brain tumor tracking, brain tumor growth 
modeling, tumor grading, and basis of deep neural network (DNN). Chapter 3 proposes 
the two methods: the feature fusion method and the joint label fusion method, for the first 
dissertation goal. Chapter 4 investigates the new WHO tumor classification criteria and 
also briefly introduces digital pathology image and proteomics information. State-of-the-
art comparison to other works is provided as well. Chapter 5 discusses the proposed 
context-aware deep learning architecture for multiple tumor analysis tasks. The chapter 
also briefly introduces the experimental data.  Finally, the dissertation concludes in 
Chapter 6, with a summary and suggestions for future work.  
Research Goal Topic Contributions 
1 Improve longitudinal brain 
tumor tracking by 
integrating tumor 
segmentation and tumor 
growth modeling 
Introduction of tumor cell 
density obtained from tumor 
growth model as novel feature 
to tumor segmentation 
prediction, and use joint label 
fusion to improve tumor 
segmentation 
2 Obtain brain tumor grading 
by analyzing phenotypic and 
proteomic information  
Development of tumor grading 
by following new WHO tumor 
criteria using a deep learning-
based method 
3 Build a robust model for 
multiple brain tumor 
analysis tasks using deep 
neural network 
Development of context-aware 
deep learning for tumor 
segmentation, tumor subtype 
classification, and overall 
survival prediction.  





This chapter reviews the relevant information on tumor segmentation, tumor growth 
modeling, longitudinal tumor tracking, tumor grading, the artificial neural network, and 
overall patient survival prediction. 
 
2.1 Brain Tumor Segmentation 
In the U.S., out of all deaths, 2.5% are caused by brain tumor. A brain tumor is a 
heterogeneous mass of tissue that is formed by an accumulation of abnormal cells. 
Compared to normal tissues, it has highly irregular properties, including multiple cell 
phenotype, heterogeneous density, high intra-tumoral pressure, and tortuous vasculature 
[28]. For diagnosis, prognosis, and treatment planning, detection and quantization of a 
brain tumor is an important step. Tumors may have an unpredictable appearance, with a 
huge variation in size, shape, and location, as shown in Figure 2. As such, the process of 
distinguishing different abnormal tumor tissues such as necrosis (NC), peritumorally 
ET NC ED NE 
Figure 2. Four cases of tumor on MRI. Note that these pre-processed images are overlaid 
with ground truth. All data obtained from BraTS Challenge. ET-enhancing tumor, NC-
necrosis, ED-peritumorally edema, NE-non-enhancing tumor. 
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edema (ED), non-enhancing tumor (NE), enhancing tumor (ET), also known as brain 
tumor segmentation, is very challenging.  
The segmentation of the various brain tumor sub-regions (i.e., ET, NE, and ED) has 
commonly been addressed as a classification problem in the existing literature [29, 30]. 
This involves robust feature extraction as  critical for such methods, followed by SVM 
and Random Forest (RF) being widely used as classifiers [13, 16, 31, 32]. The general 
idea of feature-based methods is to extract features and provide them to a classifier, in 
order to learn the most representative of the class(es) in question, and hence to obtain 
segmentation labels in new unseen cases. In recent years, deep learning has been 
successfully applied across many domains, including computer vision, speech 
recognition, and medical imaging processing (brain tumor detection and segmentation), 
among others. [29, 33, 34]. 
There are many studies proposed for image-based brain tumor segmentation in the 
literature. Among conventional machine learning-based methods, K-nearest neighbors, 
support vector machine (SVM), and AdaBoost are widely used [20, 21, 32].  In recent 
years, deep learning-based methods have been shown to outperform conventional 
machine learning-based methods for tumor segmentation. However, longitudinal brain 
tumor tracking using deep learning methods may not be feasible, as these deep learning 
methods need large amount of data and, in general, there is a lack of that large volume of 
longitudinal tumor tracking data available.   
2.2 Tumor Growth Modeling 
With tumor growth modeling, we can simulate brain tumor development over time. 
The interest of tumor growth simulation has many aspects. First, it provides a better 
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understanding of the physiology of the tumor growth. Second, a tumor growth model 
may be used to quantify a tumor’s aggressiveness for a given patient. Finally, using the 
growth model can improve therapy planning (in surgery or radiotherapy) by better 
defining the tumor invasion region based on the local estimation of the tumor cell density 
[24]. It can help in predicting the tumor over time from a limited number of patient 
observations.  
Tumor growth models can be categorized into two groups based on the observation scales 
[24]:  
•  Cellular and microscopic models. These models take the action behavior of 
individual cell into account for the subject; more complex models consider the 
interaction between the cells and the environment. 
• Macroscopic models. These models are based on local tumor cell density. Most 
of the models rely upon a reaction-diffusion equation to account for tumor 
propagation.  
Cellular and microscopic models are widely used in the literature [35-37];  however, 
these models do not consider the interactions between cells and tissues. Macroscopic 
models mainly use a reaction-diffusion formalism. These models take both the 
microscopic proliferation and the macroscopic diffusion into account for tumor growth. 
In this study, we aim to build a tumor growth model by solving the reaction-diffusion 
equation. 
 
2.3 Longitudinal Brain Tumor Tracking 
Longitudinal brain tumor segmentation prediction is not only related to the accurate 
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segmentation of the various tumor sub-regions, it also reveals information about tumor 
development over time. Monitoring longitudinal brain tumor changes is useful for the 
follow-up of treatment-related changes, the assessment of treatment response, and the 
guiding of dynamically changing treatments, including surgery, radiation therapy, and 
chemotherapy. To model and predict the growth of a tumor, a reaction-diffusion equation 
is generally employed [23, 24, 38-41]. Hu et al. simulated one-dimensional tumor growth 
based on logistic models [42]. Sallemi et al. simulated brain tumor growth based on 
cellular automata and the fast marching method [43]. Similar works for tumor growth 
prediction are proposed in [23, 24, 28, 39, 41, 44]. However, none of these methods 
explicitly obtains tumor segmentation using growth patterns as features. Clatz et al.  
proposed a GBM tumor growth simulation by solving a reaction-diffusion equation using 
the finite element method [45].  Xu et al. used phase fields to model cellular growth and 
reaction-diffusion equations for the dynamics of angiogenic factors and nutrients [46]. 
We recently proposed a novel tumor cell density feature obtained from a tumor growth 
model which assesses temporal changes of tumor cell density based on biophysical tumor 
growth modeling, for segmentation prediction [14]. 
Tumor growth modeling, combined with segmentation, is useful in understanding the 
extent of a tumor as the tumor growth. Bauer et al. proposed tumor growth-based 
segmentation [47]. Boosted Glioma Image Segmentation and Registration 
(GLISTRboost), a state-of-the-art method, is used for segmentation by incorporating a 
glioma growth model [48]. GLISTRboot utilizes a gradient boosting multi-class 
classification.  Brain Tumor Image Analysis (BraTumIA) is a tool for longitudinal brain 
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tumor segmentation [49]; however, both state-of-the-art tools ignore the internal 
relationship between different timepoint scans.  
As noted above, current works that discuss longitudinal brain tumor tracking in the 
literature highly focus on tumor segmentation,  mostly ignoring the importance of tumor 
growth. Another challenge to the work is the lack of longitudinal tracking data.  In this 
study, we propose novel methods for longitudinal tumor tracking by integrating tumor 
segmentation and tumor growth modeling with a limited amount of longitudinal MRI 
data.  
2.4 Brain Tumor Grading 
Based on the similarity of tumor cells to normal cells, the growth rate, the presence of 
definitive tumor margins, and the vascularity, they are classified as Grade I, II, III, and IV 
by the World Health Organization (WHO) [3]. Grade I tumors are the most discrete, with 
a slow growth rate. Grade II tumors have a slow growth rate, but are able to invade 
surrounding tissue.  Grade III tumors have actively reproducing abnormal cells that 
infiltrate adjacent cells, and Grade IV tumors are the most malignant, with rapid 
proliferation and infiltration to surrounding tissue [50-52]. Grades III and IV are 
categorized as high grade, and the rest are low grade.  
A new CNS brain tumor grade classification standard was released by the WHO in 
2016 [4]. Due to the drawbacks of tumor grading based only on histology, proteomics 
information has recently been used for tumor classification [53-56]. With the new 
standard for tumor grading, isocitrate dehydrogenase (IDH) mutation in proteomics 
information is identified as one of the major criteria [57]. In addition, other molecular 
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mutations, such as ATRX, X1p/19q codeletion, and MGMT have also been studied for 
glioma proteomics classification [58]. 
 
2.5 Artificial Neural Networks 
Artificial neural networks (ANNs) are computing methods inspired by the biological 
neural networks of human/animal brains. An ANN is composed of neurons, which are 
simple and interconnected processors. The neurons are interconnected for signal 
processing. The process consists of data collection, analysis and processing, network 
structure design, the number of hidden layers, the number of hidden units, initializing, 
training the network, network simulation, weights/bias adjustments, and testing the 
network [59]. ANNs are considered as a universal approximators that have the ability to 
approximate a given function distribution. A neuron is the main component of a neural 
network, and the perceptron is the most used model. Figure 3 shows a graphical 
representation of a perceptron.  
Figure 3. A graphical representation of a perceptron. 𝑥𝑖 and 𝜔𝑖 are inputs to the 
neuron and the corresponding weight, respectively. 𝑓(∙) is an active function. 𝑦 is the 
final output. 
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Label 𝑥0, 𝑥1… , 𝑥𝑛 are the inputs to the neuron. Note that the input 𝑥0 in the model is 
a fixed input that is typically set to 1 and provides a weighted external bias to the neuron. 
Each input to the neuron is multiplied with the corresponding weights, and then summed 
together. The final output is obtained by transforming the summation via an activation 
function, 𝑓(∙). The model can be mathematically written as follows: 
𝑦 = 𝑓(𝑠) = 𝑓(∑ 𝑥𝑖 ∙ 𝜔𝑖
𝑛
𝑖=0 )                                            (1) 
The popular activation functions include sigmoid, tanh function, sin/cos function, 
polynomial function, rectified linear, etc. 
 
2.5.1 Multilayer Perceptron 
A multilayer perceptron (MLP) is a class of feedforward ANN that contains one or 
more hidden layers and can learn non-linear functions. A typical MLP with a single 
hidden layer is shown in Figure 4. The leftmost layer is called the input layer. The 










Input layer Hidden layer Output layer 
Figure 4. A graphical representation of a multilayer perceptron with a 
single hidden layer. 
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MLP shows the capability to approximate any sufficiently smooth function, and it is 
regarded as a universal approximator. 
In a supervised MLP model, the ultimate goal is to minimize the error or the cost 
function between the target and the prediction obtained from the model. To adjust the 
training weights and biases using a gradient descent algorithm, the backpropagation 
algorithm is well-known for computing such gradients [61]. MLP is a popular machine 
learning solution, and it has been successfully used in diverse fields, such as speech 
recognition, image recognition, and others. 
 
2.5.2 Convolutional Neural Network   
Convolutional neural network (CNN) is a class of deep neural networks most 
commonly used for visual imagery analysis. The idea of CNN is not new, but its 
application has been limited due to memory and hardware constraints [62].  Since the 
mid-2000s, deep neural network training has been feasible because of the increased 
availability of large datasets and hardware improvements. Figure 5 shows MNIST [63] 
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A typical CNN contains convolutional layer, a pooling layer, an activation function, 
and a fully connected layer. The convolutional layer determines the output of the neurons 
that are connected to the local regions of the input through convolutional operation. The 
pooling layer performs downsampling along the spatial dimensionality of the given input, 
and further reduces the number of parameters within that activation [64]. Max pooling is 
the most commonly used for reducing the spatial size of feature maps. The activation 
function usually follows the convolutional layer. Nonlinearity between layers ensures that 
the model is more expressive than a linear model [62]. The activation functions include 
sigmoid, tanh, rectified linear unit (ReLU), and leaky-ReLU, among others. The fully 
connected layer contains neurons that are directly connected to the neurons in the two 
adjacent layers, without being connected to any layers within them [64]. It usually 
produces class scores from the activations in a classification application.  
 
2.6 CNN-based brain tumor segmentation 
In recent years, CNN-based methods have been successfully applied in medical 
imaging analysis, such as in brain tumor segmentation [33, 34], nuclei segmentation [65], 
and liver segmentation [66]. There are different methods for preparing input data for  
CNN-based tumor segmentation methods, such as patch-based [34], 2D slice-based [67], 
and 3D volume-based [33]. Each method has advantages and disadvantages.  The patch-
based method has the fastest training process, yet it may produce lots of misclassification 
in testing phase. The 2D slice-based method has a moderate training time and generates a 
more accurate result than that of patch-based method in the testing phase. The 3D 
volume-based method requires large graphic processing unit (GPU) memory. The 3D 
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volume-based method takes the longest training time, but provides the best performance 
in the testing phase, compared to the other two methods. All of the CNN architectures 
used for brain tumor segmentation have both encoding and decoding modules. The 
encoding module is used to extract the convolutional dense features, and the decoding 
module is used to reconstruct the dense features to the corresponding segmentation. The 
trainable network attempts to minimize the loss between segmentation and ground truth.   
The CNN-based method offers the best state-of-the-art performance in tumor 
segmentation. Comparing the patch-based to the 3D volume-based method, the 
improvement for the 3D method mainly depends on the computational capability of the 
GPU.  Most brain tumor cases have much more peritumorally edema than necrosis; this 
causes a data imbalance problem that may not help much for the 3D volume-based 
method in distinguishing the majority and the minority sub-tumors. We, however, 
propose a context-aware deep learning-based method that captures a global context 
information for relieving the data imbalance issue and helps to achieve better tumor 
segmentation performance. 
2.7 Patient Survival Prediction 
In general, patients with LGG have a longer survival period than those with HGG. 
Patient survival prediction is important for prognosis. Recently, the focus has been 
shifted to predicting the clinical outcome with non-invasive methods, instead of using 
invasive methods [68, 69]. There are many studies about predicting the survivability of 
patients with brain tumors in the literature [70, 71]. All of these methods extract a large 
number of radiomic image features, including shape and texture, in computed 
tomography images of the patient with brain tumors, and then apply regression methods 
   
 
20 
for survival prediction. Zeina et al. propose a feature-guide deep radiomics for 
glioblastoma patient survival prediction [69]. The authors first use a hybrid method for 
tumor segmentation, which utilizes RF and UNet, and then they extract volumetric 
features and texture features, including piecewise triangular prism surface area (PTPSA) 
and multi-fractional Brownian motion (mBm). Finally, XGBoost is applied on these 
features for the survival prediction. 
 Since hand-crafted feature extraction is very challenging, CNN may be used as a 
dense feature extraction tool. Few CNN-based methods are also proposed for survival 
prediction [72, 73]. However, many of these methods study survival prediction and 
segmentation independently, without exploring the inter-connection between survival 
prediction and tumor segmentation steps. In this work, we propose a feature-based 
method for survival prediction by integrating a tumor segmentation step using a CNN. 
 














IMPROVED LONGITUDINAL BRAIN TUMOR TRACKING 
 
3.1 Chapter Overview 
This chapter proposes a novel longitudinal brain tumor segmentation prediction using 
two different fusion approaches. The first one is called as “feature-fusion” approach, 
where unique tumor growth-based cell density and texture features are used. The second 
approach refers to label-fusion, where segmentation labels obtained from two state-of-
the-art tumor growth and stochastic texture models are utilized. In the feature-fusion-
based segmentation prediction method, we build upon a stochastic multiresolution texture 
model to obtain cell density information from tumor growth patterns as novel features 
and then fuse them with texture features. The tumor growth model is based on a reaction-
diffusion equation that is solved in 3D using a Lattice-Boltzmann method (LBM), a class 
of computational fluid dynamics method for fluid simulation. On the other hand, the 
proposed joint label-fusion method fuses segmentation labels obtained from a hybrid 
generative-discriminative brain tumor segmentation method that incorporates a 
biophysical tumor growth model and the stochastic tumor segmentation models, to 
achieve tumor segmentation predictions. For traditional multi-atlas label fusion, multiple 
target images are registered and weighted by comparing target image to multiple atlas 
images. Further, the reference labels are obtained by considering tissue labels from 
registering the target image to the atlas images. In this study, due to the presence of 
multiple tumors in the provided mMRI volumes, we did not use healthy atlases as 
reference images, but instead created consensus average images across all patients for 
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each MRI modality. The reference labels are obtained by the RF and the GB 
segmentation models. The fusion weight is obtained proportional to inverse of intensity 
difference by target images to reference images. 
 
3.2 Literature Review 
This section provides a brief literature review on brain tumor segmentation, tumor 
segmentation prediction. 
3.2.1 Brain Tumor Segmentation 
Brain tumors may be classified as benign or malignant based on grade, and primary 
or metastatic based on origin. According to the World Health Organization (WHO), 
tumors of the central nervous system (CNS) may be graded as I, II, III and IV, based on 
multiple factors including similarity of tumor cells to normal cells, growth rate, presence 
of definitive tumor margins, and vascularity. Among these classes, grade III tumors 
contain actively reproducing abnormal cells that infiltrate between adjacent cells, and 
grade IV tumors are the most malignant with rapid tumor cell proliferation and 
infiltration to surrounding tissues [51, 52]. Recently, WHO suggested a new CNS tumor 
classification, based on both phenotype and genotype expressions in addition to growth 
pattern and behaviors [4]. Glioblastoma (formerly glioblastoma multiforme, GBM) is the 
most common and deadly among all human primary CNS tumors [5], with extensive 
heterogeneity radiographically reflected by various sub-regions, comprising enhancing 
(ET) and non-enhancing tumor (NET), as well as peritumorally edematous/invaded tissue 
(ED). Glioblastoma originates from glial cells and grows by infiltrating surrounding 
tissues. Even though there have been many treatment advancements, the median overall 
survival period of patients diagnosed with GBM still remains 12-16 months [5].  
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The segmentation of the various brain tumor sub-regions (i.e., ET, NET, and ED) has 
commonly been addressed as a classification problem in existing literature [29, 30], with 
robust feature extraction being critical for such methods, and SVM and convolutional 
neural networks (CNN) being widely used as classifiers. The general idea of feature-
based methods is to extract features and provide them to a classifier, to learn the most 
representative of the class(es) in question, and hence obtain segmentation labels in new 
unseen cases. However, to the best of our knowledge, tumor cell density pattern has not 
been used as a feature in tumor segmentation prediction by others. The cell density 
feature can be obtained from solving the biophysical tumor growth modeling such that to 
predict potential tumor development in the future. 
Brain tumor detection, segmentation, and tracking its changes over time (henceforth, 
tumor segmentation prediction) is of particular importance for diagnosis, treatment 
planning, and monitoring. In practice, manual tumor segmentation by radiologists is 
tedious, time consuming and prone to human error. Brain tumor segmentation over time 
is a critically challenging task due to its unpredictable appearance, infiltration to 
surrounding tissue, intensity heterogeneity, size, shape, and location variation [18]. There 
are many brain tumor segmentation techniques published in the literature. Gooya et al. 
introduced a generative approach for registering a probabilistic atlas of a healthy 
population to brain MRI scans with glioma and simultaneously segmenting these scans 
into tumor and healthy tissue labels [40, 74]. Cuadra et al. proposed an atlas-based 
segmentation of pathological brain MRI scans using a lesion growth model [75]. Bauer et 
al. also introduced an atlas-based segmentation of brain tumor images using a Markov 
random field-based tumor growth model and non-rigid registration [47]. However, these 
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atlas-registration based techniques may be tedious and error prone since they require 
accurate deformable image registration of tumor bearing slices with the atlas. To avoid 
the issues with image registration, other studies consider the brain tumor segmentation as 
a feature-based classification problem. Islam et al. extracted sophisticated texture features 
among others and applied the AdaBoost algorithm to segment tumors [76]. Reza et al. 
proposed an improved texture features based multiple abnormal brain tissue classification 
method using Random Forest (RF) [17, 77]. Support vector machine (SVM) has also 
been used as a classifier for brain tumor segmentation [21]. In addition, others have 
utilized super-pixels to classify tumor tissue. Wang et al. used a graph-based 
segmentation technique to over-segment images into homogeneous regions [78, 79]. Pei 
et al. applied simple linear iterative clustering (SLIC) to obtain super-pixel [22]. 
Kadkhodaei et al. applied a semi-supervised “tumor-cut” method to over-segment 
images. The super-pixel-based segmentation relies on the quality of the approach used for 
the over-segmentation. Finally, over recent years, various approaches based on CNN 
have been used for brain tumor segmentation [29, 80].   
 
3.2.2 Longitudinal Brain Tumor Tracking 
Longitudinal brain tumor segmentation prediction is not only related to the accurate 
segmentation of the various tumor sub-regions, but also reveals information about the 
tumor development over time. Monitoring longitudinal brain tumor changes is useful for 
follow-up of treatment-related changes, assessment of treatment response and guiding 
dynamically changing treatments, including surgery, radiation therapy, and 
chemotherapy. Figure 6 shows a longitudinal brain tumor example for a patient from 
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BraTS 2015 patient dataset [18]. This figure shows that enhancing, necrosis and other 
surrounding tissues of the tumor for an example patient in timepoint 2 are evolving 
















To model and predict the growth of a tumor, a reaction-diffusion equation is generally 
employed [23, 24, 38-41]. Hu et al. simulated one-dimensional tumor growth based on 
logistic models [42]. Sallemi et al. simulated brain tumor growth based on cellular 
automata and fast marching method. However, none of these methods explicitly obtains 
tumor segmentation using growth patterns as features. Clatz et al. proposed a GBM 
tumor growth simulation by solving the reaction-diffusion equation using finite element 
method [45].  Xu et al. used phase fields to model cellular growth, and reaction-diffusion 
Figure 6. A longitudinal brain tumor example. Top row from left to right: T1, T1c, 
T2, T2-FLAIR, and ground truth (GT) at timepoint 1. Bottom row shows the 
corresponding images at timepoint 2 (282 days after timepoint 1). 
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equations for the dynamics of angiogenic factors and nutrients [46]. We recently 
proposed a novel feature, which assesses temporal changes of tumor cell density, based 
on biophysical tumor growth modeling, for segmentation prediction [21]. Meier et al. 
used a fully automatic segmentation method for longitudinal brain tumor volumetry [49]. 
However, Meier’s work only focuses on analyzing each timepoint independently, and 




In this section, we discuss texture features, random forest (RF) classification, tumor 
growth modeling, and joint label fusion. 
3.3.1 Multi-fractal Brownian Motion (mBm) Texture Feature Extraction 
The mBm is a nonstationary zero-mean Gaussian random process that corresponds to 
the generalization of fractional Brownian motion (fBm) [17]. The fBm considers a rough 
heterogeneous appearance of tumor texture in brain MRI. In the fBm process, the local 
degree of Hurst index (H) is a constant. The value of 𝐻 determines the randomness of the 
fBm process. However, tumor texture in MRI may appear as a multifractal structure that 
is a time (t) and/or space varying process and is represented by mBm. The mBm process 
is defined as 𝑥(𝑎𝑡) = 𝑎𝐻(𝑡)𝐻(𝑡), where 𝑥(𝑡) is the mBm process with a scaling factor, 𝑎, 
and the time varying Hurst index 𝐻(𝑡). The mBm features effectively model spatially 
varying heterogeneous tumor texture. Its derivation combines the multi-resolution 
analysis enabling one to capture spatially varying random inhomogeneous tumor texture 
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at different scales [76]. More details for these multiscale texture features and their 
efficacy in brain tumor segmentation can be found in [17, 76, 77]. 
3.3.2 Random Forest Classification 
Random forest (RF) is an ensemble learning method for classification, regression, and 
other tasks [81]. The RF classifier is heavily used for medical image analysis due to its 
very fast, and efficient multi-class handling capability. Assume there are 𝑛 samples and 
(?⃑?𝑖)𝑐?⃑?𝑖=1
𝑛  feature vectors with outcomes 𝑦𝑖. Data is represented as: 𝐷 =
[(?⃑?1, 𝑦1),⋯ , (?⃑?𝑛, 𝑦𝑛)]. The feature vector (𝑑 dimension) of a sample ?⃑?𝑖 is represented by 
?⃑?𝑖 = (𝑣𝑖1, ⋯ , 𝑣𝑖𝑑). A classification tree is a decision tree, in which each node has a 
binary decision based on whether ?⃑?𝑖 is less than a threshold 𝛼. At each node, feature 𝑣𝑖𝑑 
and threshold 𝛼 are chosen to minimize resulting ‘diversity’ in the children nodes that are 
measured by Gini criterion. Ensemble of classifiers ℎ = [ℎ1(?⃑?),⋯ , ℎ𝐾(?⃑?)] and we define 
parameters of the decision tree for each classifier ℎ𝑘(𝑥) to be 𝜃𝑘 = (𝜃𝑘1, 𝜃𝑘2, ⋯ , 𝜃𝑘𝑝). 
We can write: ℎ𝑘(?⃑?) = ℎ(?⃑?|𝜃𝑘). A RF classification is based on a family of classifiers 
[{ℎ(?⃑?|𝜃𝑘), 𝑘 = 1,⋯ ,𝐾}] with parameters 𝜃𝑘, which are randomly chosen from a model 
vector 𝜃.  
In RF classification, given a fixed ensemble ℎ = [ℎ1(?⃑?),⋯ , ℎ𝐾(?⃑?)], where ?⃑? is a 
random vector and 𝐾 is the number of trees in the forest, the estimated probability for 






𝑡=1 ,                                       (2) 
where pt(𝒸|?⃑?) is the estimated density of class labels at the 𝑡
𝑡ℎ tree. The final multi-class 
decision function of the forest is defined as: 





𝑝(𝒸|?⃑?),                                      (3) 




,                                                     (4) 
where ?̅? is the mean correlation between pairs of trees in the forest, and 𝑠 is the strength 
of the set of classifiers.  
3.3.3 Biophysical Tumor Growth Model 
Tumor growth describes an abnormal growth of tissue, which usually involves cell 
proliferation, invasion, and mass effect to the tumor surrounding tissues. During cell 
invasion, tumor cells migrate as a cohesive and multicellular group with retained cell-cell 
junctions and penetrate to surrounding healthy tissues. Tissues in the brain may deform 
due to mass effect. Biophysical tumor growth modeling simulates the interactive process 
occurring between the abnormal tissue (i.e., tumor) and the surrounding brain tissues, and 
parameterizes the collective changes in the brain, including death, infiltration to 
surrounding tissues, and proliferation. The reaction-diffusion equation has been widely 
used to model brain tumor growth [23, 39, 41, 42], using a diffusion and a logistic 
proliferation term given as: 
𝜕𝑛𝑠
𝜕𝑡
= 𝐷𝛻2𝑛𝑠 + 𝜌𝑛𝑠(1 − 𝑛𝑠),                                             (5) 
𝐷𝛻𝑛𝑠. ?⃗? 𝜕Ω = 0,                                                (6) 
where 𝑛𝑠 is the tumor cell density, 𝐷 is the diffusion coefficient while infiltrating, and 𝜌 
is the proliferation rate. Equation (5) enforces Neumann boundary conditions on the brain 
domain Ω, and ?⃗?  is unit normal vector on the 𝜕Ω pointing inward to the domain. 
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3.3.4 Joint Label Fusion 
Joint label fusion has been developed in recent years and used for analysis of medical 
images [22, 78]. Comparing to the single-atlas based method, multi-atlas-based label 
fusion reduces errors associated with any single atlas propagation in the process of 
combination, and the weight for each atlas is computed independently. However, 
different atlases may produce similar label errors. To solve this issue, Wang et al. 
proposed an advanced multi-atlas label fusion, known as joint label fusion [82]. Multi-
atlas label fusion enforces co-registration with sample images to target image and 
minimizes independent errors to improve the segmentation result [83]. In general, the 
label map ?̂? is computed by using the following equation: 
?̂? = 𝑎𝑟𝑔𝑚𝑎𝑥
𝐿
𝑝(𝐿|𝐼; 𝐼𝑛, ∅𝑛),                                             (7) 
where 𝐼𝑛 is the n-th training image, and ∅𝑛 is the transfer function during image 
registration. 𝐿 is the candidate label map of the testing image 𝐼. Joint label fusion 
achieves consensus segmentation given as, 
?̅? = ∑ 𝜔𝑖(𝑥)𝑝(𝑙|𝑥, 𝐼𝑛),
𝑛
𝑖=1                                                 (8) 
where 𝜔𝑖(𝑥) is individual voting weight, and 𝑝(𝑙|𝑥, 𝐼𝑛) is the probability that 𝑥 votes for 







,                                                         (9) 
where 1𝑛 = [1; 1;⋯ ; 1] is a vector of size 𝑛 and 𝑀𝑥 is the pairwise dependency matrix 
that estimates the likelihood of two atlases both producing wrong segmentations on a per-
voxel basis for the target images. 
The dependency matrix is computed as: 




𝑚 (Ʊ(𝑥(𝑗))) − 𝑇𝐹
𝑚(Ʊ(𝑥))| , |𝐴𝐹
𝑚 (Ʊ(𝑥(𝑘))) − 𝑇𝐹
𝑚(Ʊ(𝑥))|〉
𝐿𝑀
𝑚=1 ,       (10) 
where 𝑚 indices correspond to all modality channels, and |𝐴𝐹
𝑚 (Ʊ(𝑥(𝑗))) − 𝑇𝐹
𝑚(Ʊ(𝑥))| 
is the vector of absolute intensity difference between a selected atlas image and the target 
image over local patches Ʊ centered at voxel 𝑥(𝑗) and 𝑥, respectively. 〈∙,∙〉 is the dot 
product. 𝐿𝑀 is the total number of modalities [82]. 
3.4 Methods 
This study proposes two distinct methods for longitudinal brain tumor segmentation 
prediction: a feature-based and joint-label fusion-based. Application of the proposed 
methods, assumes appropriate pre-processing of the provided multimodal MRI brain scans, 
consisting of noise reduction, bias field correction, scale standardization, and histogram 
matching. 
3.4.1 Feature Fusion Based Method 
The method proposed in this study utilizes tumor growth patterns as novel features to 
improve texture-based tumor segmentation in longitudinal MRI. The proposed pipeline is 
shown in Figure 7. 
By using the proposed feature-based fusion, the vector 𝑣  is defined as: 
𝑣 = [𝐹𝐷, 𝑛𝑠 , 𝐼𝑝𝑟𝑒, 𝐼𝑝𝑜𝑠𝑡 , ⋯ , 𝐻𝑖𝑠𝑡],                                 (11) 







𝑡=1 ,                            (12) 
where 𝒸 is the candidate label of the target image. 𝐾 is number of trees applied. ?⃑? is a 
feature vector. θk is the classifier parameter obtained from training process at 𝑘
𝑡ℎ tree. 
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𝐹𝐷 describes the mBm features, 𝑛𝑠 is the tumor cell density as derived by the tumor 
growth model (Eq. 5), 𝐼𝑝𝑟𝑒 and 𝐼𝑝𝑜𝑠𝑡are the image intensities before and after intensity 
normalization (scale standardization [84]), respectively. 𝐻𝑖𝑠𝑡 is the intensity histogram of 
all modalities (T1, T1c, T2, and T2-FLAIR). 
Figure 7. Pipeline of the proposed method. At the 1st scan date, we extract texture 
(e.g., fractal, and mBm) and intensity features, and obtain the ground truth label 
map for different brain tissues from baseline pre-operative (i.e., first timepoint) 
multimodal MRI scans. The ground truth at this first timepoint is used to obtain the 
tumor growth modeling and enable to predict cell density for the next timepoint. 
Finally, considering the cell density pattern as a new feature, we fuse it with other 
features using a RF classifier to generate the label of second timepoint. 
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Two feature types were used in the proposed method, representing local and spatial 
descriptors. Local features comprise the intensity of each modality before and after 
scaling standardization, as well as after histogram matching, their pairwise intensity 
differences among image modalities, and the cerebrospinal fluid (CSF) mask, obtained by 
the CSF expected intensity across modalities. Spatial features include a fractal feature 
extracted from multi-modal MRI, named piecewise-Triangular Prism Surface Area 
(PTPSA), the mBm features that combine both multiresolution-fractal and wavelet 
analyses for each modality after scaling standardization, and 6 gabor-like Texton 
features. 
3.4.2 Joint Label Fusion Based Method 
Label fusion has been successfully used for tumor segmentation in recent years [82, 
83]. The method proposed here employs joint label fusion for improving tumor 
segmentation prediction by fusing stochastic feature-based tumor labels, with 
segmentation labels obtained from a hybrid generative-discriminative brain tumor 
segmentation method that incorporates a biophysical tumor growth model, namely 
GLISTRboost [48, 85, 86] (GB). The proposed pipeline is shown in Figure 8. Initially, 
Figure 8. Pipeline for joint label fusion-based tumor segmentation prediction. 
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GB is applied on the 2nd timepoint in parallel with independent application of the RF-
based approach, and their output segmentation labels are then fused together leading to 
the consensus result. 
All provided MRI scans were affinely co-registered to an atlas template [87] and 
skull-stripped by BraTS. We then scaled all modality intensities for one reference subject 
to the range [0-255] and then matched the histograms of each modality across all 
subjects. The error dependence matrix (Eq. 10) was then computed between the target 
and the reference image, which describes the consensus average images across all 
patients. By using the error dependency matrix, we calculate the voting weight (Eq. 9), 
and finally the agreement label (Eq. 8) is obtained. 
In GB, the probabilities of ET and NE are defined as: 
𝑓(𝑌|𝛷, ℎ, 𝑞) = ∏ ∑ 𝜋𝑘(ℎ(𝑥)|𝑞)𝑓𝑘(𝑦(𝑥)|𝛷)
𝐾
𝑘=1𝑥∈𝛺 ,             (13) 
where 𝑌 is the observation set, 𝛷 is the intensity distribution, ℎ the reference domain, 𝑞 
the tumor growth model parameters, 𝜋𝑘 the 𝑘 abnormal tissue, and 𝑓𝑘(∙) is a multivariate 
Gaussian distribution. 
Application of the joint label fusion method requires all four provided MRI volumes, 
the label map 𝐿𝐺𝐵 obtained by GB (Eq. 14), and the segmentation result 𝐿𝑅𝐹 obtained by 
Eq. 3 and 4. The voting weights are obtained by computing the error dependency matrix 
from all the available modalities to the reference images (Eq. 10). For calculating the 
dependency matrix (Eq. 10), Ʊ(𝑥) is a 5 × 5 × 5 patch centered at location 𝑥. 𝐴𝑚 (𝑚 ∈
[1, 2, 3, 4] describes the volumes T1, T1c, T2, and T2-FLAIR of the training images, 
respectively. 𝑇𝑚 is the target image. A is the reference image including the GB 
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segmentation (AGB) and RF classification (ARF). The candidate labels at location 𝑥 for 
either the GB or the RF segmentations are defined as: 
𝑝(𝑙|𝑥) = ∑ 𝜔𝑥(𝑖)𝑝(𝑙|𝑥(𝑖), 𝐴(𝑖))
2












𝑝(𝑙|𝑥(2), 𝐴𝑅𝐹) ,        (14) 
Let’s define Dirac delta function 𝛿(𝑙|𝑥) as 1, if the predicted label is the same as the 













𝛿𝑅𝐹(𝑙|𝑥) ,     (15) 
where the dependency matrix of 𝑀 is computed by using Eq. 10. In the special case of 












= 0.5, then the Eq. 15 
will be simplified as a majority voting method, and 𝑝(𝑙|𝑥) = 0.5(𝛿𝐺𝐵(𝑙|𝑥) + 𝛿𝑅𝐹(𝑙|𝑥)). 
Therefore, it is recommended to choose an odd number of templates. 
3.4.3 Lattice-Boltzmann Method for Tumor Growth Modeling 
To solve the reaction-diffusion equation (Eq. 5), different methods such as finite 
element method (FEM) [24] and Lattice-Boltzmann method (LBM) [41] may be used. 
We use the LBM method, due to its computational efficiency and easy parallelization. 
The LBM is defined as [88]: 
𝑓𝑠(𝑥 + 𝑒 𝑖 , 𝑖 , 𝑡 + 1) − 𝑓𝑠(𝑥 , 𝑖 , 𝑡) = 𝛺𝑆
𝑁𝑅 + 𝛺𝑆
𝑅,                                  (16) 
where 𝑓𝑠(𝑥 , 𝑖 , 𝑡) is the one particle distribution function of specifies 𝑠 with velocity 𝑒 𝑖 at 
time 𝑡 and dimensionless position 𝑥 . ΩS
NRis non-reactive term. 𝛺S






,                                                   (17) 
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where 𝜏 is the relaxation time. 𝑓𝑠
𝑒𝑞(𝑥 , 𝑖 , 𝑡) is the equilibrium distribution function, which 
depends on 𝑥  and 𝑡 corresponding to a system with zero mean flow given as: 
𝑓𝑠
𝑒𝑞
= 𝜔𝑠,𝑖𝑛𝑠                                                       (18) 
Two-dimensional nine-velocity (D2Q9) model is commonly used in 2D cases. The 
nine discrete velocities are shown in Figure 9.  
 
Figure 9. Illustration of the nine discrete velocities in a D2Q9 model. 
Let’s define: 
𝑛𝑠(𝑥 , 𝑡) = ∑ 𝑓𝑠(𝑥 , 𝑖 , 𝑡) = ∑ 𝑓𝑠
𝑒𝑞(𝑥 , 𝑖 , 𝑡)𝑖𝑖 ,                                          (19) 
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+ 𝜌𝑛𝑠(1 − 𝑛𝑠),                                               (21) 
𝛺𝑆
𝑅 = 𝜌𝑛𝑠(1 − 𝑛𝑠),                                                              (22) 
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)  offers solution for Eq. 5. 




Initialize the diffusion coefficient D & proliferation rate 𝜌 for a specific tissue. 
Initialize weights (Eq. 20). 
Set boundary for LBM working space.  
Initialize 𝑛𝑠 as a matrix with tumor density at starting position. 
Repeat until set time limit is reached. 
/*Assignment*/ 
For 𝑖 = 1: 9 
    Streaming step: move 𝑓𝑠 → f𝑠
∗ in direction of e⃗ i. 
    If the cell hits the boundary 
       Tumor cell moves in opposite direction with same speed. 
    Else  
   Compute 𝑓𝑠
𝑒𝑞
 (Eq. 18).          
   Collision step: calculate the updated distribution function 𝑓𝑠 (Eq. 16).   
  End 
End 
Compute cell density 𝑛𝑠 (Eq. 19). 
Figure 10. Algorithm for solving the biophysical tumor growth model using LBM. 
 
3.4.4 Longitudinal Tumor Segmentation Prediction 
By longitudinal tumor segmentation prediction, we refer to the accurate delineation of 
the tumor boundaries in any follow up timepoint, given the segmentation of the tumor in 
the first scan. This does not only allow for the segmentation of the tumor but it also 
reveals information about its longitudinal growth and aggressiveness/behavior. 
For feature fusion-based method, we build a tumor growth model by solving the 
reaction-diffusion equation using LBM. Diffusion coefficient 𝐷 and proliferation rate 𝜌 
are important parameters to simulate tumor growth using the model. To predict tissues 
growth using the model, the parameters of the model are suggested within 
[0.02, 1.5]𝑚𝑚2/𝑑𝑎𝑦, and [0.002, 0.2]/𝑑𝑎𝑦 [41]. We empirically set 𝐷𝑁𝐶, 𝜌𝑁𝐶 as 0.052, 
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0.01, 𝐷𝐸𝐷, 𝜌𝐸𝐷 as 0.06, 0.009, 𝐷𝑁𝐸, 𝜌𝑁𝐸 as 0.03, 0.014, 𝐷𝐸𝑇, 𝜌𝐸𝑇 as 0.05, 0.01 for NC, 
ED, NE, and ET, respectively. For the JLF method, we integrate a stochastic texture 
feature-based segmentation with another state-of-the-art, named GLISTRboost (GB) to 




The brain tumor scans used to quantitatively evaluate the proposed methods in this 
study belong to retrospective longitudinal multi-institutional cohorts of patients 
diagnosed with glioblastoma, from the publicly available Multimodal BRAin Tumor 
Segmentation (BraTS 2015) challenge dataset [18]. Nine patients with longitudinal 
multimodal MRI (mMRI) scans with growing tumors along time were chosen from the 
BraTS 2015 dataset. The brain scans for each patient consist of four MRI modalities, 
namely native T1-weighted (T1), contrast-enhanced T1-weighted (T1c), T2-weighted 
(T2) and T2 Fluid-attenuated inversion recovery (T2-FLAIR). 
Note that we use the BraTS 2015 dataset instead of the latest BraTS 2018 dataset [18, 
86], as the latter provides only pre-operative mMRI scans, whereas the BraTS 2015 data 
describes paired combinations of pre- and post-surgical mMRI brain scans for each 
patient, with isotropic resolution images of size 240*240*155. The manually evaluated 
ground truth labels of these brain scans were also available, allowing for the quantitative 
validation of the proposed methods. These ground truth labels delineate the tumor sub-
regions of necrotic/fluid-filled core (NC), non-enhancing/solid tumor (NE), ET, ED, and 
everything else grouped together, with labels of 1, 3, 4, 2, and 0, respectively. 
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3.5.2 Performance Evaluation 
In the BraTS dataset, the ground truth is manually annotated by qualified raters, 
following a hierarchical majority voting rule [18]. To quantitatively evaluate the proposed 
brain tumor segmentation prediction method, a criteria policy is required. Specifically, 
there are three different tumor regions, as defined by the BraTS challenge [18]: 
1) Region 1 – Whole tumor (WT) 
This region defines the whole tumor (WT). Consistent with the BraTS challenge [18], 
the WT consists of the union of all tumor labels. Although the ED is a peripheral tissue to 
the tumor core, it is still considered as part of the WT since it is not pure edema but also 
includes invaded tumor cells. 
2) Region 2 – Tumor core (TC) 
This region defines the tumor core (TC), which comprises the combination of NC, NE 
and ET. Note that the TC describes what is typically resected during surgery. 
3) Region 3 – Enhancing tumor (ET) 
The ET region biologically represents regions of contrast leakage through disrupted 
blood-brain barrier. 




) [89], where 𝐴 and 𝐵 represent the segmentation labels of a given method 
and the manually annotated (i.e., ground truth) labels. The DSC value ranges in [0,1], 
where 0 represents that the two comparing regions do not have any overlap and 1 means 
that the regions are identical.  




3.6.1 Experiment with Feature Fusion-Based Method 
To solve the biophysical brain tumor growth model using LBM, three parameters 
need to be considered: diffusion coefficient 𝐷, proliferation rate 𝜌 and simulated days 𝑡. 
The diffusion coefficient and proliferation rate are variable to the model. Choosing a 
value for these variables is challenging. The values we used for 𝐷 is within [0.02, 
1.5] 𝑚𝑚2/𝑑𝑎𝑦, and 𝜌𝜖[0.002, 0.2]𝑑𝑎𝑦−1, after considering the available literature [41]. 
Figure 11 shows an example of longitudinal tumor growth using the proposed method 
and as depicted by ground truth labels in a single slice for a patient in the BraTS 2015 
dataset. 
We then apply the tumor growth model to real patient data from the BraTS dataset, 
where each patient’s scan includes information of all sub-regions, i.e., NC, ED, NE, and 
ET. We simulate all these abnormal tissues separately, and then fuse them all into the 
final label map of the patient. Parameters vary among the various tissues [41]. By using 
the LBM model, we obtain the cell density patterns for the NE, ET, and the WT tissues, 
respectively. Note that the WT comprises all sub-regions including ED and NC. 
Following previous work [17], we use a total of 30 features including fractal, mBm, 
intensity and intensity difference among MRI modalities.  
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For specification of Eq. 12, label 𝑐 ∈ (0, 1, 2, 3, 4) which represents background, NC, 
ED, NE, and ET, respectively. 𝐾 is empirically chosen as 20, and number of random 
features is 4, which is approximately equal to the square root of total number of features. 
Addition of cell density as a feature, results in 30 features (density of NC, ED, NE, and 
ET) extracted from each MRI slice. Figure 12 gives an illustrative example of comparing 
two cases between tissue segmentation obtained before and after adding cell density as a 
Figure 11. An example of longitudinal tumor growth by using proposed method for 
one slice of patient 439. (top left) Simulated NC with D = 0.052, ρ = 0.01. (top 
middle). ED with D = 0.06, ρ = 0.009. (top right) NE with D = 0.03, ρ = 0.014. 
(bottom left) ET with D = 0.05, ρ = 0.01. (bottom middle) Fused label and (bottom 
right) ground truth of the second scan data. 
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feature type for a patient. 
We evaluate the performance of the proposed method and compare the DSC to the 
segmentation prediction without cell densities features (Figure 13). We further evaluate 
the statistical significance of the obtained results using paired t-test for all patients. The 
𝑝-values for segmentation prediction obtained with and without inclusion of the cell 
density feature show statistical significance for WT, TC, and ET tissues (Table 2). The 
paired t-test analysis shows that fusion of tumor growth pattern with texture and intensity 
features offers a significant improvement in the segmentation prediction of TC and ET 
tissue regions. However, the statistical analysis does not suggest significant improvement 
Figure 12. Examples of tumor segmentation prediction by using the proposed method. 
(Left column) Without cell density feature, (middle column) With cell density feature, 
and (right column) the ground truth of second time scan. 
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for the WT tissue. We hypothesize that the reason for this is that the WT label, which 
Figure 13. Comparison of tumor growth prediction segmentation using proposed 
method. Vertical line and “+” indicates the median and the mean, respectively. 
   
 
43 
represents the abnormal T2-FLAIR signal, is well-segmented by the originally applied 
method (GB, or RF) and hence there is not substantial significant improvement offered 
by the proposed method. 
Table 2. Paired t-test for comparison of the volume between without and with cell density 
by using RF only to predict the tumor segmentation labels in timepoint 2, using data from 
timepoint 1. 
 DSCWT DSCTC DSCET 
Result w/o cell density 0.251±0.08 0.229±0.08 0.311±0.101 
Result with cell density 0.314±0.16 0.332±0.065 0.448±0.076 
𝑝-value  0.150 0.0002 0.0002 
 
3.6.2 Experiment with Joint Label Fusion-Based Method 
We apply the joint label fusion-based brain tumor segmentation prediction to process 
data from all nine patients at timepoint 2 (post-op scans). To evaluate the performance, 
we use a Leave-One-Out cross-validation schema to compute the DSC of segmentations 
at timepoint 2 from the proposed method and compare to the ground truth and to 
segmentations generated by GB [48, 86] (Figure 14). An example segmentation 
prediction result is shown in Figure 15. From the collective summary of comparisons, we 
note that the proposed method offers better results than GB alone. The result DSC for the 
proposed method is 0.850±0.055 for WT, 0.836±0.041 for TC, and 0.837±0.0074 for 
ET. 
We also statistically evaluate the segmentation prediction results using ANOVA and 
the resulting 𝑝-values are shown in Table 3. The joint label fusion-based (JLF) method 
offers statistically significant improvements on tumor segmentation performance for the 
WT and ET regions, when compared to the results of the GB method. The overall 
performance is better than GB and RF across all patients, as shown in Figure 14. 





Figure 14. DSC comparison results among GB, RF, and proposed method (JLF) at 
time 2. Vertical line and “+” indicates the median and the mean, respectively. 








Figure 15. An example of label fusion-based application. The first (top) row denotes 
the input brain scans. Rows 2-4 illustrate shows the axial, sagittal, and coronal views, 
respectively, of the T1c input can overlaid with GB, RF, JLF and GT labels. 
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Table 3. Performance of 3D brain tumor growth prediction segmentation. 
 WT TC ET 
Average DSC by GB 0.810±0.095 0.829±0.062 0.796±0.104 
Average DSC by RF  0.852±0.063 0.812±0.074 0.851±0.083 
Average DSC by JLF 0.850±0.055 0.836±0.041 0.837±0.0074 
Median DSC by GB 0.8177 0.8266 0.7557 
Median DSC by RF 0.8369 0.843 0.8743 
Median DSC by JLF 0.8544 0.8372 0.81 
𝑝-value (GB and JLF)  0.047 0.579 0.023 
In addition, we also compare the proposed work with BraTumIA (BTIA) [49], a state-
of-art tool that has been previously used for brain tumor segmentation in longitudinal 
scans. We applied BraTumIA to the patient data used in our experiments and the obtained 
results shown the superiority of our proposed approach (Table 4). Results for all 
experiments are also given in false positive and false negative rates (Appendix B). 
Table 4. Longitudinal tumor segmentation comparison of average DSC between 
BraTumIA [49] and JLF. 
 𝐷𝑆𝐶𝑊𝑇 𝐷𝑆𝐶𝑇𝐶 𝐷𝑆𝐶𝐸𝑇 
BraTumIA [49] 0.761±0.104 0.703±0.186 0.732±0.140 
JLF  0.850±0.055 0.836±0.041 0.837±0.075 
 
3.7 Discussion 
In this Chapter, we propose two methods for longitudinal brain tumor segmentation 
prediction, in longitudinal mMRI. Feature fusion using RF and tumor cell density offers 
improved performance for predicting longitudinal tumor growth. Specifically, this 
method shows significant prediction improvement of TC and ET abnormal tissues, while 
there is no significant improvement for WT tissue. On the other hand, the joint label 
fusion using RF and GB labels shows improvement on WT and ET abnormal tissues over 
that of the GB labels alone. Note due to availability of limited number of longitudinal 
tumor growth patient cases used in this study, the segmentation prediction performance is 
not optimal for all possible types of abnormal tissue.  




BRAIN TUMOR GRADING USING PHENOTYPE AND PROTEOMICS 
INFORMATION 
 
4.1 Chapter Overview 
This chapter proposes a joint analysis of histopathology and proteomics patient data 
using DNN for improving brain tumor grade type and subtype classification following 
new WHO tumor grade criteria. The work utilizes digital pathology images and four 
pieces of proteomics information (IDH, X1p/19q codeletion, ATRX, and MGMT) to 
obtain improved tumor classification accuracy. In addition, a specific shape-based 
measure for abnormal cell nuclei known as cellularity [90] is investigated for its efficacy 
in tumor subtype classification. Cellularity is used to indicate the probability of cancerous 
cells of the whole slide image (WSI). Specifically, our work discovers the potential role 
of cellularity in histopathology image and IDH type in proteomics data for subtype 
classification within Grade III brain tumor. 
 
4.2 Introduction 
Gliomas are primary brain tumors that originate from glial cells. Survival period of 
the glioma patients is highly related to the tumor type and grade. According to a recent 
report, five-year (2011- 2016) survival rate is 94.1% for pilocytic astrocytoma yet it is 
only 5.6% for glioblastoma [2]. Overall, 94.1% of patients with pilocytic astrocytoma 
(LGG grade II), 57.6% of patients with anaplastic oligodendroglioma (LGG grade III), 
30% of patients with anaplastic astrocytoma (LGG grade III) survived five years after 
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diagnosis [2]. Therefore, accurate tumor classification and grading may help in making 
proper treatment planning and assessing overall prognosis in clinical practice. 
Prior to 2016, the World Health Organization (WHO) standard for brain tumor 
classification has been based on only the histologic appearance in pathologic slides. 
Tumor grade is classified according to the microscopic similarities with different putative 
cells of origin and differentiation level [4]. The histological features of mitotic activity, 
microvascular proliferation and necrosis are used when grading the diffuse glioma. There 
are many studies in the literature for tumor grading using histopathology images [91-93]. 
As only histopathology data for tumor grading is no longer accurate and efficient, a new 
CNS brain tumor grade classification standard has been released by WHO in 2016 [4]. 
Due to the drawbacks of tumor grading based only histology, proteomics information has 
recently been used for tumor classification [53-56]. With the new standard for tumor 
grading, isocitrate dehydrogenase (IDH) mutation in proteomics information is identified 
as one of the major criteria [53].  
Computational methods provide an additional method in analyzing proteomics and 
histopathology data. There are only few works that focus on tumor grade classification 
using both histopathology and proteomics information in the literature. Most of the tumor 
classification and grading manuscripts still focus on non-invasive structural MRI and 
proteomics information [94-96]. These works have specific limitations. First, for the 
structural MRI-based methods, the authors need to extract manually identified features 
before further analysis. Secondly, they may classify gliomas by using MRI and 
proteomics information separately. There has been intense work in literature using Deep 
Neural Network (DNN) for brain tumor classification [92, 97-99]. DNN is capable of 
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automatically learning features from raw data for classification of tumor types. A typical 
convolutional neural network consists of an input layer, multiple hidden layers, and an 
output layer. The hidden layers typically include convolution layers, activation function 
layers, pooling layers, and fully connected layers. 
 
4.3 Background 
CNS tumor grade classifications has been an intense research area. Based on the 
different types of patient data, tumor classification and grading methods are generally 
categorized in two groups: digital pathology-based, and proteomics-based methods. 
There have been a few works in non-invasive MRI-based tumor grading. Zacharaki et al. 
use a support vector machine (SVM) based machine learning method to classify brain 
tumor on combining conventional anatomic MRI and perfusion MRI. Their method 
achieves 96% accuracy for distinguishing LGG and HGG using leave-one-out cross 
validation [100]. Fusun et al. use a SVM to grade gliomas based on multi-parametric 
MRI [95]. In [96], authors use  a machine learning based method for molecular subtyping 
of gliomas by analyzing the radiomics data. However, these methods may not be suitable 
for clinical use [100-103]. 
4.3.1 Digital Pathology-Based Method 
Digital pathology images have been the primary source for tumor grade classification 
prior to the most recent WHO grade criteria. There are many works on tumor 
grading/classification in the literature. Yonekura et al. propose an improved disease stage 
classification using a convolutional neural network for glioma histopathology images 
[104]. They obtain classification accuracy is 87.15% for differentiating LGG and HGG. 
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Ertosun et al. propose a gliomas grading method using convolutional neural networks 
(CNN) [98], which achieves good results. Even though histopathology-based tumor grade 
classification of low-grade gliomas has been used widely, it is not suitable to predict 
clinical outcomes due to high intra- or inter-observer variability [91, 105]. Because of 
inaccurate tumor grade classification using only histopathology information, clinicians 
usually consider genetic classification to guide clinical decision-making for treatment 
planning and management of patients with brain tumors [53, 56, 106, 107]. 
4.3.2 Proteomics-Based Method 
Proteomics studies of brain tumors have been critical to understand the proteomics 
underpinnings of neoplasms. For infiltrating gliomas, proteomics classification are more 
reliably reflected underlying tumor biology than traditional morphology [108].  
proteomics underpinning of primary central nervous system has changed the perspective 
to tumor diagnosis and classification [108]. Few works study tumor grade by introducing 
proteomics information. IDH mutation has shown to be present in about 80% of LGG 
grade II and grade III and secondary HGG [109].  IDH 1/2 encodes the Krebs or citric 
acid cycle family of metabolic enzymes [54]. Furthermore, patients with IDH-mutated 
gliomas have significantly longer survival than for those with IDH wild-type tumor [55]. 
On the other hand, there are some works on tumor grading using histopathology data in 
the literature. Kong et al. proposed a computer-aided classifying grade of neuroblastic 
differentiation on whole-slide histology images [110]. Using a method called sequential 
floating forward selection (SFFS), the authors first segment nuclei, extract hand-crafted 
features, apply feature selection method and finally use k-nearest neighbor for 
classification. Barker et al. propose an automated brain tumor type classification in 
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whole-slide digital pathology images using local representative tiles [93]. In another 
work, nuclei segmentation is obtained by using hysteresis thresholding and 
watershedding, feature selection, and an Elastic Net Classification for brain tumor 
grading. In [92], Mousavi et al. proposed an automated brain tumor grade discrimination 
based on spatial domain analysis. The authors developed a method for cell segmentation 
and a customized operation of spatial and morphological filters to identify microvascular 
proliferation, then apply a hierarchical decision for LGG and HGG classification. 
Molecular mutation, such as IDH 1/2, ATRX, 1p/19q codeletion, TERT, and MGMT have 
also been studied for glioma proteomics classification [58].   
Following the relationship between IDH mutation status and glioma classification, 
Chang et al. utilized a residual convolutional neural network to determine IDH status in 
low- and high- grade glioma from MR imaging [111]. By analyzing Japanese glioma 
patients with IDH mutations, Mukasa et al. found that IDH mutation with intact 1p/19q is 
useful when assessing prognosis of LGG grade III patients [57]. A strong association has 
been found between IDH canonical mutations and the alpha thalassemia/mental 
retardation syndrome X-linked (ATRX) mutation, whereas X1p/19q codeletion and ATRX 
loss barely exists simultaneously [112]. Leeper et al. proposed a better proteomics 
classification method using X1p/19q codeletion, IDH mutation, and ATRX for grade II 
diffuse glioma [113]. In addition ,the O6-methylguanine-DNA methyltransferase  
(MGMT) is believed to have been associated with longer survival in patient with 
glioblastoma (HGG) [114]. In Reference [107] the authors study glioma groups based on 
X1p/19q, IDH and telomerase reverse transcriptase (TERT) promoter mutation in tumors. 
They found that proteomics groups are interpedently associated with overall survival 
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among LGG grade II and grade III patients, but not among patients with glioblastoma. 
All these studies suggest that there is a lack of methods using both histopathology and 
proteomics data for tumor type and subtype classification as suggested by the latest WHO 
guidelines. Consequently, the proposed method in this work analyzes pathology images 




In the section, we discuss image pre-processing (color normalization), cellularity and 
the proposed method using DNN for glioma type and subtype grading. 
4.4.1 Pre-processing of Histopathology Data 
In histopathology, tissue sample images are commonly stained by a combination of 
hematoxylin and eosin (H&E). Hematoxylin binds to nuclei with a bluish-purple, and 
eosin stains acidophilic proteins with a red-pink. The stained tissue biopsies and 
microarrays are easy sharing and analyzing with computer algorithm [115]. However, 
due to the color corresponding to difference in slide scanners, there is an undesirable 
variation in color, which results in image interpretation difficulty. Color normalization 
can help both pathologists and software in comparing different tissue sample by 
standardizing image appearance. In this work, we utilize a structure-preserving color 
normalization and sparse stain separation proposed in [116] to normalize H&E stained 
tissue images. A given RGB image is converted to an optical density (𝑋) based on Beer-
Lambert law, then the stain separation is decomposed by non-negative constraints on the 
stain density (𝐿) and color appearance matrix (𝑊), which yields, 
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𝑗=1 ,                         (23) 
subjects to, 
  𝑊, 𝐿 ≥ 0, ‖𝑊(: , 𝑗)‖2
2 = 1,                                   (24) 
where 𝜆 is sparsity and regularization parameter. 𝑟 is the number of stains. 
Then, the stain separation of source (𝑋𝑠) and target 𝑋𝑡 images are needed to factorize into 
color appearance and stain density map (𝑊𝑠𝐿𝑠 and 𝑊𝑡𝐿𝑡). To preserve structure color 
normalization, we normalize the color appearance of a source image 𝑠 to a target image 𝑡.  
Finally, we combine a scaled version of the density map with color appearance of the 
target image to create the normalized source image. It can be expressed as: 
𝐿𝑠





𝑅𝑀(𝑗, : ), 𝑗 = 1,⋯ , 𝑟,                 (25) 
𝑋𝑠
𝑛𝑜𝑟𝑚 = 𝑊𝑡𝐿𝑠
𝑛𝑜𝑟𝑚,                                            (26) 
where 𝐿𝑖
𝑅𝑀 = 𝑅𝑀(𝐿𝑖) ∈ 𝑅
𝑟×1, 𝑖 ∈ 𝑠, 𝑡 and RM computes the pseudo maximum of each 
row vector at 99%. The registered normalized source image is recovered by:  
𝐼𝑠
𝑛𝑜𝑟𝑚 = 𝐼0 𝑒𝑥𝑝(−𝑋𝑠
𝑛𝑜𝑟𝑚),                                (27) 
where 𝐼0 is the illuminating light intensity on the sample [116]. 
Figure 16 shows three examples of color normalization for different types of H&E tiles. 
Case A is a LGG grade II that shows oligodendroglioma with mutant IDH, wild-type 
(WT) ATRX, X1p/19q codeletion and Methylated MGMT. Case B is a LGG grade III 
which has astrocytoma with mutant IDH, mutant ATRX, non-codeletion of 1p/19q, and 
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unmethylated MGMT. Case C is a HGG that contains glioblastoma with WT IDH, WT 
ATRX, non-codeletion of X1p/19q, and unmethylated MGMT. 
 
4.4.2 Cellularity in Histopathology Data 
Assessment of cellularity is an important component of tumor burden assessment. 
Cellularity is usually estimated by pathologists in clinical practice and has been used in 
Figure 16. Three color normalization instances representing LGG grades II, III, and 
HGG. Top row showing original H&E, and bottom row showing the normalized H&E 
using proposed method. Column from left to right: case A (LGG grade II), case B (LGG 
grade III), and c (HGG). 
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breast cancer analysis [90, 117]. The cellularity of any given image is computed as the 
ratio of the area of a cancerous cell over the whole image area. Nuclei segmentation 
followed by dilation of the cancerous cell is needed for computing the cellularity, then 
the cellularity is calculated by area of dilated cancerous cell area over the whole image 
area. Morphological dilation step is applied on the malignant nuclei to expand the 
malignant cancerous cells that may account for the presence of cytoplasm around each 
nucleus [90, 118]. The dilation size is set as 11 as in [90, 118]. Cellularity value ranges 
within 0 and 1. In our case, the dilation size is empirically set as 12. In general, LGG 
grade II is defined to have a small cellularity value while HGG has a large value of 
cellularity. Nuclei segmentation is implemented by using a deep learning based UNet 
method [119]. 
4.4.3 Proposed Tumor Grading Method 
We use a cascaded convolutional neural network as the underlying model for tumor 
grading [11]. A multi-class (LGG grade II, LGG grade III, and HGG) classification 
problem is posed as step-wise binary classification problem. In the first step, we 
discriminate HGG and LGG using a regular DNN. For LGG, we further apply a residual 
neural network (ResNet [120]) to distinguish between LGG II and III. The proposed 
pipeline is shown in Figure 17. Note as our proposed method utilizes both digital 
pathology images and proteomics information, the resulting pipeline uses two types of 
DNNs. Finally, cellularity information is introduced to improve tumor type and subtype 
grading performance. 
Accurate classification of LGG grade II from LGG grade III is more challenging as 
the two tumor types have very similar histopathologic appearance. The DNN model used 
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for LGG grade II/III is similar to that of LGG/HGG, however, the network contains more 
layers which may capture a subtle differences between two similar tumor grades. A 
ResNet architecture is used at the second step. The structure details of these DNNS are 
listed in Table 5.  
 
Figure 17. The pipeline has two parts: cellularity and grade classification. In 
cellularity part, nuclei segmentation of the input H&E is implemented using UNet 
architecture with Multi-Organ nuclei segmentation data set. Cellularity is computed by 
using the dilated image. For grade classification part, we use a cascaded DNN for 
distinguish tumor grade. The first DNN (DNN1) is to classify HGG and LGG, and the 
second DNN (DNN2) is to distinguish LGG II and III. In DNN module, we attach the 
proteomics information (IDH, ATRX, X1p/19q codeletion and MGMT) to the fully 
connected layer. For Resnet, there is a skip connection within each block. 
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Table 5. Deep neural network structures for CNN and ResNet. We show the data size of 
each layer. In each convolution block, it has 1 convolution layer, 1 ReLU layer, and 1 
max pooling layer. We construct a more complex neural network for differentiating LGG 
II/III by considering the much similarity within them. 
Layers Output size of CNN Output size of ResNet 
   Input 512*512*3 512*512*3 
Conv. block 1 256*256*8 256*256*8 
Conv. block 2 128*128*16 128*128*16 
Conv. block 3 64*64*32 64*64*32 
Conv. block 4 32*32*64 32*32*64 
Conv. block 5 16*16*128 16*16*128 
Conv. block 6 8*8*256 8*8*256 
Conv. block 7 4*4*512 4*4*512 
Conv. block 8 - 2*2*512 
Conv. block 9 - 1*1*1024 
   FC layer 1 8192 1024 
FC layer 2 128 128 
FC layer 3 2 2 
4.5 Experiments and Results 
4.5.1 Data 
We use 96 public digital diagnostic whole slide hematoxylin and eosin (H&E) stained 
histopathology images with proteomics and clinical information from The Cancer 
Genome Atlas (TCGA). The 96 whole slide image (WSI) contains 28 LGG grade II, 36 
LGG grade III and 32 HGG. Each WSI can be larger than 1 GB. In order to process this 
large size image, we divide the WSI into multiple tiles with size 1000 × 1000. 
Therefore, we have an overall 96 tiles for the study. We select one tile as a reference, 
then apply color normalization for the rest of the tiles, so that all tiles have a similar color 
appearance that preserves original structure. For nuclei segmentation, the training H&E 
straining data is obtained from Multi-Organ nuclei segmentation challenge, which 
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contains 30 images and around 22000 nuclear boundary annotations for several organ 
tissues [65, 121].  
To evaluate the proposed method, we use 8-fold cross validation. The dataset is 
randomly split as training and testing data based on tumor grade of LGG grade II, LGG 
grade III, and HGG with ratio 8:2. Moreover, in order to increase data sample, we crop 
sub-regions of patches with size of 512 × 512. In addition, we also apply data 
augmentation techniques (random rotation of 90°, 180°, 270°, random flipping image 
along axis, and random scaling image by 0.95~1.1) to increase the number of training 
samples. 
In our experiments, we consider IDH1/2, ATRX, X1p/19q, and MGMT as the 
proteomics information. The proteomics information distribution used in this work is 
listed in Table 6. There are four histologic glioma subtypes in the experimental data: 
astrocytoma (AA), oligoastrocytoma (OA), oligodendroglioma (OD), and glioblastoma 
(GBM). It is worth noting that oligoastrocytoma is strongly discouraged in new WHO 
classification [4]. 








Mutant 25 27 1 
Wild-type 3 9 31 
ATRX 
Mutant 14 14 0 
Wild-type 13 22 17 
N/A 1 0 12 
X1p/19q 
Non-codeletion 22 29 32 
Codeletion 6 7 0 
MGMT 
Unmethylated 4 9 13 
Methylated 24 27 8 
NA 0 0 11 
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4.5.2 Experiments  
First, we compute the cellularity feature as shown in Figure 18. The Figure shows 
three examples of cellularity. In general, patients with HGG have high value of 
cellularity, and small cellularity value for low-grade patients.  
As discussed above we use a cascaded convolutional neural network for pairwise 
tumor grade classification. The proposed DNN is implemented using PyTorch 1.0 on 
high-performance clustering with Nvidia V-100 GPU. The minibatch size is set as 2 as 
Figure 18. Three examples of tumor cellularity. Column one, two, three 
are color normalized image, segmentation, dilated segmentation image, 
respectively. Row1, Row2, and Row 3 are showing LGG grade II, LGG 
grade III, and HGG, respectively. Cellularity of Row 1, 2, and 3 are 
0.4972, 0.4402, and 0.7582, respectively. 
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the tile size is large and maximum training epoch is set as 80. We use a binary cross-
entropy as the objective function. In training phase, we minimize the cross-entropy loss 
[122] to optimize the model as follows: 
𝑙𝑜𝑠𝑠 = −∑ 𝑝(𝑥) 𝑙𝑜𝑔(𝑞(𝑥))∀𝑥 ,                                                            (28) 
where 𝑝 is the true distribution, and 𝑞 is the estimated distribution of class. In training 
phase, we use Adam [123] optimizer with initial learning rate of 𝑙𝑟0 = 0.001, and the 
learning rate (𝑙𝑟𝑖) is gradually decreased as: 
𝑙𝑟𝑖 = 𝑙𝑟0 ∗ (1 −
𝑖
𝑁
)0.9,                                                                 (29) 
where 𝑖 is epoch counter, and 𝑁 is a total number of epochs in training.  
 
4.5.3 Tumor Type Classification 
To investigate the impact of networks and cellularity, we compare the classification 
performance by using different network with and without cellularity. The average of 
accuracy over 8-fold cross validation is shown in Table 7. 






HGG vs LGG 
No cellularity 94.91% 95.18% 
Cellularity 95.34% 94.42% 
Grade II vs III 
No cellularity 67.71% 69.06% 
Cellularity 66.80% 76.54% 
Table 7 shows that the type of network and cellularity does not have noticeable 
impact on discrimination of HGG versus LGG. In comparison, cellularity shows 
improvement in the ability of ResNet to capture subtle difference between grade II and 
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III, and may help to significantly improve the classification accuracy for these two tumor 
types. The confusion matrix of the proposed method for ResNet with cellularity is shown 
in Table 8. 
Table 8. Confusion matrix of the proposed method using image patches. In the method, 
we use CNN for discriminating HGG and LGG, and ResNet for distinguishing LGG 
grade II and III. Both are with cellularity.  
 Predicted class A
ctu
al class 
 LGG grade II LGG grade III HGG 
LGG grade II 601 371 36 
LGG grade III 154 1107 36 
HGG 1 89 1063 
 
This experiment investigates effect of different combinations of patient data using 8-
fold cross validation for tumor type classification. The result is shown in Table 9. The 
regular CNN model offers the best performance when all information (pathology image, 
proteomics information, and cellularity) is considered with the best performance of 
95.34% ± 4.67% for discrimination of LGG vs HGG. ResNet offers the best result with 




   
 
62 
Table 9. Performance comparison by applying proposed method for different data 
information. 
Tumor Type 
Pathology, proteomics and 
radiology information  




CNN 92.48% ± 
5.30% 
Pathology + proteomics 
CNN 94.41% ± 
3.69% 
Pathology + cellularity 
CNN 93.43% ± 
4.95% 
Pathology + proteomics + 
cellularity 






ResNet 64.84% ± 
7.57% 
Pathology + proteomics 
ResNet 68.89% ± 
8.87% 
Pathology + cellularity 
ResNet 66.23% ± 
6.11% 
Pathology + proteomics + 
cellularity 
ResNet 76.54% ± 
7.24% 
 
4.5.4 Tumor Subtype Classification 
In this experiment, we study the effect of cellularity feature in discriminating between 
IDH mutation status that may indicate glial aggressiveness within a specific type of brain 
tumor. The results show potential correlation between cellularity and IDH types as shown 
in Table 10. It shows the average cellularity value and variance among different grade 
gliomas.  
For LGG grade III and HGG, cellularity of glioma patient with Wild-type IDH is 
higher that of Mutant IDH. Note that cellularity of Wild-type IDH of LGG grade III 
(0.45) is close to that of Mutant IDH of HGG (0.44). Cellularity of glioma patient with 
Grade III, IDH 1/2 wild-type acts aggressively as that of glioblastoma patient with IDH 
1/2 mutant type. This result suggests that one may predict IDH type, and hence, the tumor 
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subtype (aggressiveness) using the cellularity information. Table 10 also shows that 
cellularity of patient with IDH-mutant type is higher than that of wild type for LGG grade 
II.  
Table 10. Average cellularity and variance for all grade gliomas with IDH type in our 
data. 
Tumor grade IDH mutant-type IDH wild-type 
LGG grade II 0.3769±0.0761 0.3908±0.1029 
LGG grade III 0.4012±0.0834 0.4500±0.0920 
HGG 0.4419 0.5580±0.1014 
 
4.5.5 State-of-the-art Comparison 
We compare our result in this work with existing works in the literature as shown in 
Table 11. Note that the comparison is qualitative rather than quantitative as the patient data, 
methods, and number of patients are all different for these works. The comparison Table 
shows that for tumor type classification, our work is comparable in differentiating HGG vs 
LGG, and offers the best performance on distinguishing LGG grade II vs LGG grade III. 
With addition of proteomics information, our proposed method offers the highest accuracy 
for LGG grade II vs. grade III classification.  
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Table 11. Performance comparison with state-of-art. Accuracy percentage in bold is the 
best result in the comparison. “-” sign indicates the data is non-available. 

























































































We further compare the preformation of tumor subtype classification using our 
proposed method to the state-of-the-art. We achieve tumor subtype classification accuracy 
71.42%, 62.31%, 68.18%, 96.77% for astrocytoma (AA), oligoastrocytoma (OA), 
oligodendroglioma (OD), and Glioblastoma (GBM), respectively.  In comparison the 
authors in [126], report accuracy of  65.85%, 46.50%, 60.26%, and 95.54%, for the same 
tumor subtypes as  shown in Table 12. Note unlike [126] our proposed method in this work 
report both tumor type and subtype classifications following the new WHO criterion.   
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Table 12. Tumor subtype classification comparison to state-of-the-art. 
  AA OA OD GBM AO 
Work in [126] 65.85% 46.50% 60.26% 95.54% 25% 
Our method 71.42% 62.31 68.18% 96.77% - 
 
4.6 Conclusion 
In this Chapter, we propose a deep learning-based method for improving brain tumor 
type and subtype grading using both pathology and proteomics data following the new 
2016 WHO classification. The classification method integrates a cellularity feature which 
is derived from morphology of histologic images to improve classification performance. 
The experiments show that while type of DNN may not be critical in discrimination of 
low-grade from high-grade glioma, DNN may have significant impact for discriminating 
grade II versus grade III. Moreover, we investigate the impact of proteomics and 
cellularity information on glioma grading. An interesting finding of this work is that the 
cellularity features show promise in prediction of subtype of LGG grade III with IDH 
mutation. Specifically, for patient with LGG grade III, cellularity of wild-type IDH is 
higher than that of mutant-type, suggesting that cellularity feature obtained from 
pathology image may be used to classify more aggressive wild-type IDH subtype of LGG 
grade III. These findings may be beneficial to tumor prognosis and treatment planning. In 
the future, we plan to apply the proposed method for larger patient data to validate the 








BRAIN TUMOR SEGMENTATION, TUMOR SUBTYPE CLASSIFICATION, 
AND SURVIVAL PREDICTION USING DEEP NEURAL NETWORK 
 
5.1 Chapter Overview 
This chapter proposes context-aware deep learning for brain tumor segmentation, 
subtype classification, and overall survival prediction using structural multimodal 
magnetic resonance images (mMRI). We first propose a 3D context-aware deep learning, 
that considers uncertainty of tumor location in the radiology mMRI image sub-regions, to 
obtain tumor segmentation. We then apply a regular 3D convolutional neural network 
(CNN) on the tumor segments to achieve tumor subtype classification. Finally, we 
perform survival prediction using a hybrid method of deep learning and machine 
learning. To evaluate the performance, we apply the proposed methods to the Multimodal 
Brain Tumor Segmentation Challenge 2019 (BraTS 2019) dataset for tumor segmentation 
and overall survival prediction, and to the dataset of the Computational Precision 
Medicine Radiology-Pathology (CPM-RadPath) Challenge on Brain Tumor 
Classification 2019 for tumor classification.  The online evaluation performance suggests 
that the proposed method offers robust tumor segmentation and survival prediction, 
respectively. Furthermore, the tumor classification results in this work was ranked second 
place in the testing phase of the 2019 CPM-RadPath global challenge. 
 
5.2 Background 
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Gliomas are the most common primary brain malignancies, with varying degrees of 
aggressiveness, variable prognosis and various heterogeneous regions [1]. In the US, the 
overall average annual age-adjusted incidence rate for all primary brain and other central 
nervous system (CNS) tumors has been reported as 23.03 per 100,000 population during 
2011-2015 [2]. For patients with malignant tumors, the estimated five- and ten- year 
relative survival rates are 35.0% and 29.3%, respectively, according to the report from 
2011-2015 [2]. The median survival period of patients with glioblastoma (GBM) is about 
12-15 months [5]. Diagnosis of tumor subtype and grade is vital for treatment planning 
and prognosis of the patients. According to a 2016 report of World Health Organization 
(WHO), classification of tumors in the CNS is based on both phenotype and genotype 
(i.e., IDH mutation and X1p/19q codeletion status) [4]. However, structural imaging such 
as magnetic resonance imaging (MRI) is continued to be used for identifying, locating, 
and classifying brain tumors [13, 100, 127, 128]. Tumor subtypes include diffuse 
astrocytoma, IDH-wildtype/-mutant, oligodendroglioma, IDH-mutant and 1p/19q-
codeleted, glioblastoma, IDH-wildtype, etc. [4]. Traditional machine learning-based 
methods, such as support vector machines (SVM), k-nearest neighbors algorithm (KNN), 
and random forest (RF) are generally utilized for brain tumor analysis [14, 15, 31, 94, 
129-131]. However, these methods have the common limitation of hand-crafted feature 
extraction in the modeling phase.  
Deep learning-based methods overcome the drawback of hand-crafted feature 
extraction. Deep learning has made it possible to build large-scale trainable models that 
have the capacity to learn the optimal features required for a given task. Deep learning is 
powerful and outperforms traditional machine learning in many fields, such as computer 
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vision [132-134], medical image segmentation [119, 135], and speech recognition [136]. 
Deep learning is fundamentally composed of a deep neural network structure with several 
layers. An artificial neural network utilizes a backpropagation algorithm to decrease the 
error between the prediction and ground truth. However, training artificial neural network 
models becomes more difficult as the number of layers increase [137]. Deep neural 
network training has been feasible since the mid-2000s, which brought about increased 
availability of large datasets and hardware improvements.  
As a standard protocol for brain tumor characterization, MRI is able to capture a 
diverse spectrum of tumor phenotypes [138]. Multimodal MRI (mMRI) provides 
comprehensive tumor information. For example, post-contrast T1-weighted (T1ce) 
images are well-known to be correlated with blood brain barrier (BBB) disruption, while 
T2-weighted (T2) and T2 Fluid Attenuated Inversion Recovery (FLAIR) images are well-
known for capturing tumor margins and peritumoral edema [138]. This suggests that the 
phenotypic differences at the cellular level are also reflected in the imaging phenotype 
(appearance and shape). While mMRI captures comprehensive brain tumor information, 
extracting this information through brain tumor analysis, such as tumor segmentation, 
remains challenging because of the similar phenotypic appearance of abnormal tissues in 
mMRI images. Figure 19 shows the intensity distribution of three types of abnormal brain 
tissues in T1, T1ce, T2, and FLAIR images for a representative case. These intensity 
distributions are highly similar for tumor tissues for all patients in this study. While on 
T1ce image, enhancing tumor (ET) is easily separable from others, the necrosis (NC) and 
peritumoral edema (ED) have nearly the same intensity distribution. 
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Brain tumors have been studied for many years. However, most works study tumor 
segmentation, classification, and overall survival prediction independently, ignoring the 
underlying relationship among these critical analysis tasks. In this work, we propose a 
complete framework for brain tumor study, including tumor segmentation, subtype 
classification, and overall survival prediction by analyzing mMRI via a deep learning-
based neural network architecture. 
 
Figure 19. Intensity distribution of necrosis, edema, and enhancing tumor on T1 (top left), 
T1ce (top right), T2 (bottom left), and FLAIR (bottom right) images of one case. 




There are many methods reported in the literature on brain tumor segmentation that 
include intensity-based, atlas-based, deformable model-base, hybrid-based, and deep 
learning-based methods [139]. Recently, deep learning-based methods offered better 
performance for tumor segmentation [29, 33, 34]. For tumor classification, both non-
invasive structural MRI and pathology images are utilized to classify brain tumors [126, 
140, 141]. Overall survival prediction is to estimate the remaining life span of a patient 
with brain tumors. Most existing work is based on traditional machine learning and linear 
regression [1, 142].  
Figure 20 illustrates an overview of the proposed framework. In A, there are four raw 
MRI modalities: T1, T1ce, T2, and FLAIR. The raw images are pre-processed in B, 
including co-registration, skull-stripping, noise reduction, etc. We then perform a z-score 
normalization for the brain region only to have zero mean and unit standard deviation. 
Subsequently, the proposed Context Aware Deep Neural Network (CANet) is applied to 
segment tumor as shown in C. The segmentation results are shown in D. In E, a 3D CNN 
is utilized to classify tumor using the segmented abnormal tissues. In F, we extract high-
dimensional features using front-end of the CANet, and then apply a linear regression for 
overall survival prediction. 






5.3.1 CNN-Based Tumor Segmentation 
An overview of the proposed context-aware deep learning method for tumor 
segmentation is shown in Figure 21. The proposed CANet captures global texture 
features and utilizes semantic loss to regularize the training error [143] [119]. The 
A: Raw T1, T1ce, T2, and FLAIR 
T1 
T2 






T1 T1ce T2 FLAIR 
E: Tumor subtype classification F: Survival Prediction 
C: CANet 
Figure 20. Overview of the methodology and overall work flow. 
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architecture consists of encoding, context encoding, and decoding modules. The encoding 
module extracts high-dimensional features of the input. The context encoding module 
produces updated features and a semantic loss to regularize the model. The decoding 
module reconstructs the feature maps to an output prediction, so that we compute the 
difference between the reconstructed output and input images as a regularizer. 
 
Figure 21. Overview of the proposed CANet architecture for tumor segmentation. It 
consists of encoding, decoding, and context encoding modules. Encoding and decoding 
module are UNet-like symmetric. Context encoding module produces semantic loss. 
5.3.2 CNN-Based Tumor Classification 
Figure 22. Overview of CNN-based tumor classification. At the last convolutional layer, 
we apply an average pooling layer to shrink the size. 
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The pipeline for tumor classification is shown in Figure 22. Overview of CNN-based 
tumor classification. At the last convolutional layer, we apply an average pooling layer to 
shrink the size. In this work, the segmented tumor uncertainty in subregions (ET, TC, and 
WT) from the above section are used as the input of the proposed tumor classification 
model. We use a regular CNN-based architecture for tumor classification. The 
probabilities of tumor subregions are convolved and down sampled, then passed through 
three fully connected layers to achieve classification. 
 
5.3.3 Hybrid Method for Survival Prediction 
Instead of extracting features and using a traditional machine learning approach, we 
utilize the proposed CANet to extract high-dimensional features. We believe that the 
extracted features from tumor segmentation are associated with overall survival. The 
features are then selected using the LASSO method [144]. Finally, we apply a linear 
regression to the selected features for overall survival prediction (as shown in Figure 23). 
 
5.4 Experiments and Set UP 
5.4.1 Data Description 
Figure 23. Pipeline of proposed method for overall survival prediction. 
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In this work, the experimental data is obtained from Multimodal Brain Tumor 
Segmentation Challenge 2019 (BraTS 2019) [1, 12, 145-147] for brain tumor 
segmentation and overall survival prediction and Computational Precision Medicine: 
Radiology-Pathology Challenge on Brain Tumor Classification 2019 (CPM-RadPath 
2019)  [148] for tumor classification. The BraTS 2019 dataset includes training, 
validation, and testing data. The training data has a total of 335 cases consisting of 259 
HGG and 76 LGG cases. There are 102 cases obtained from The Cancer Imaging 
Archive (TCIA) [149], and the rest are from private dataset. Only cases with gross total 
resection (GTR) are evaluated for overall survival prediction. In addition, there are 
another independent 125 and 166 cases for the validation and testing phases, respectively. 
Note that, the grading information, resection status, and ground truth are privately owned 
by the challenge organizer and not available for public use. For the CPM-RadPath 2019 
dataset, training, validation, and testing data are also provided. There are 221, 35, and 73 
cases for training data, validation data, and testing data, respectively. Ground truth is 
available for only the training data. In both datasets, the multimodal MRIs have been pre-
processed by the organizers following the protocol in [145]. The summary of gender 
information for both training datasets is shown in Table 13.  









Male Female Unknown 
Tumor segmentation  90 76 169 335 
Tumor classification 52 46 123 221 
Survival prediction 65 41 104 210 
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For segmentation, the tumor ground truth consists of one/more abnormal tissue(s): 
necrosis (NC), peritumoral edema (ED), and enhancing tumor (ET). However, 
performance evaluation is based on tumor sub-regions: enhancing tumor (ET), tumor core 
(TC), and whole tumor (WT), where TC consists of ET and NC. WT is a combination of 
TC and ED. For tumor classification, there are three subtypes: lower grade astrocytoma 
with IDH-mutant (Grade II or III), oligodendroglioma with IDH-mutant, X1p/19q 
codeleted (Grade II or III), and glioblastoma and diffuse astrocytic glioma with 
proteomics features of globlastoma, IDH-wildtype (Grade IV). For overall survival 
prediction, there are three categories: short-term (<10 months), mid-term (between 10-15 
months), and long-term (>15 months). 
 
5.4.2 Experimental Setup 
All experiments in this study are performed in accordance with relevant guidelines 
and regulations as approved by the institutional IRB committee at Old Dominion 
University. 
Experiment 1: brain tumor segmentation. A total of 335 patients are used for training, 
and 125 patients are used for validation. Note that the ground truths of the validation 
dataset are not available to public. At the validation and testing phases, we submit the 
segmentation results to the challenge portal for BraTS 2019 Online evaluation [150]. For 
the hyperparameters of the proposed context-aware deep learning, the initial learning rate 
is set to 0.0001, and decays gradually to 0 at the end of training. Total number of epochs 
is set to 500. The Adam optimizer is used [123] for gradient descent optimization. In 
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order to prevent overfitting in the training phase, we apply the Leaky-Relu activation 
function and drop out with a ratio of 0.2.  
Experiment 2: brain tumor classification. There are 221 cases provided in the training 
phase. We randomly take 80% of the data as training, and use the remaining 20% as our 
own validation set, while maintaining the same proportion of each tumor subtype in each 
set. The ground truth of the validation and testing data are privately held by the challenge 
organizer. In validation phase, we submit the results for CPM-RadPath online evaluation 
[26]. The hyperparameters are similar to those used in tumor segmentation, but with total 
number of epochs is set to 2000. Note that for the testing phase, challenge participants are 
required to submit the wrapped algorithm using Docker [151], a platform to develop, 
deploy, and run applications inside containers, and tested by the organizer. The ranking is 
based on the performance evaluated by the organizer. Throughout the process, only the 
challenge organizer is involved in the testing evaluation. 
Experiment 3: overall survival prediction. For the training phase, we randomly split 
the training data into 80% and 20% sets for training and validation, respectively, while 
maintaining the same proportion of cases from each risk category in each set. We then 
apply the trained model to the validation data for online evaluation, and finally apply to 
the testing data for ranking. The training hyperparameters are similar to that of tumor 
segmentation, but with total number of epochs is set to 1000.  
 
5.4.2 Evaluation Metrics 
For tumor segmentation, dice similarity coefficient (DSC) and Hausdorff distance are 
used to measure the segmentation quality [89]. DSC quantifies the overlap between two 
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subsets. It is computed as 𝐷𝑆𝐶 =
2|𝐴∩𝐵|
|𝐴∪𝐵|
 [89], where A and B are two subsets. DSC of 0 
means no overlap at all between the subset A and B. DSC of 1 indicates that the subsets 
are perfectly overlapped. Hausdorff distance measures how far two subsets of a metric 
space are from each other. It is calculated as 𝑑𝐻(𝐴, 𝐵) = max{ℎ(𝐴, 𝐵), ℎ(𝐵, 𝐴)}, where 




‖𝑎 − 𝑏‖, ‖∙‖ is the norm operator [152]. Smaller Hausdorff distance 
means that the two subsets are closer. For evaluation of tumor classification and overall 
survival prediction, accuracy, and mean square error (MSE) are used.  
 
5.5 Results and Contributions 
5.5.1 Results  
Experiment 1: brain tumor segmentation. Figure 24 shows a visual comparison of 
tumor tissue segmentation in axial, coronal, and sagittal views for a representative case 
for BraTS 2019. The dice similarity coefficient (DSC) and training loss changes are 
shown in Figure 25. The quantification performance of the validation dataset offered by 
online evaluation is shown in Table 14. In the Table, row one is the performance without 
post-processing, while row two is the performance with post-processing steps that 
includes small object removal and hole filling. We then test the proposed method with 
BraTS 2019 dataset consisting of 166 cases with unknown tumor grade. The online 
evaluation offers average DSC of 0.8133, 0.8867, and 0.84031 for ET, WT, and TC, 
respectively. According to the performance comparison in Table 14, DSC of WT is 1% 
lower than in the validation phase. However, DSC of ET and TC shows 6% and 4% 
improvement in the testing phase. Note that the Hausdorff distance in the testing phase is 
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consistently lower than that of the validation phase. These results suggest that our model 
























Figure 24. Comparison of tumor segmentation using the proposed method and 
ground truth. Top row from left to right: T1ce image, segmented tumor overlaid 
with T1ce in axial view, in coronal view, and in sagittal view. Bottom row from 
left to right: FLAIR image, ground truth overlaid with T1ce in axial view, in 
coronal view, and in sagittal view. 
Figure 25. The DSC and loss changes in training stage. 
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Table 14. Dice coefficient results for tumor segmentation in the validation and testing 
datasets. 
Phase Post-







Validation No 0.73856 0.90496 0.81496 4.09623 4.91633 6.80917 
Validation Yes 0.77273 0.90496 0.81496 3.22012 4.91633 6.80917 
Testing Yes 0.8133 0.8867 0.84031 2.22904 4.78833 4.14805 
 
Experiment 2: tumor classification. We applied the proposed method to CPM-
RadPath 2019 validation dataset,  then wrapped the trained model using Docker [151], 
and shared with the CPM-RadPath Challenge organizer. In the testing phase, the 
organizer executed the wrapped algorithm to obtain tumor subtype classification result 
for the final competition. The online performance of validation (35 cases) and testing 
datasets (73 cases) is shown in Table 15. In the testing phase, our result is ranked at 2nd 
place [27]. 
Table 15. Online evaluation of tumor classification on CPM-RadPath 2019 validation and 
testing datasets. 
Phase Dice Average Kappa Balance_acc F1_micro 
Validation 0.749 0.764 0.715 0.749 0.829 
Testing 0.596 NA 0.39 0.596 0.603 
 
Experiment 3: overall survival prediction. There are only 29 valid cases in BraTS 
2019 validation dataset. Our accuracy is 0.586 using online evaluation, as shown in Table 
16. In the testing phase (107 cases), the proposed method offers an accuracy of 0.439 
with mean square error (MSE) of 449009. 
Table 16. Survival prediction performance of the validation dataset obtained from online 
evaluation. 
Phase Accuracy MSE medianSE stdSE SpearmanR 
Validation 0.586 79146 24362 113801 0.502 
Testing 0.439 449009 44604 1234471 0.279 
 




To the best of our knowledge, brain tumor segmentation, tumor subtype 
classification, and overall survival prediction have been studied independently, ignoring 
the inherent relationship among them. In this work, we propose an integrated method for 
brain tumor segmentation, tumor subtype classification, and overall survival prediction 
using deep learning and machine learning methods. The specific contributions are as 
follows. 
First, we propose a context-aware deep learning-based method for brain tumor 
segmentation. Second, we utilize a hybrid method for overall survival predication. 
Specifically, we extract high-dimensional features using the proposed context aware 
based convolutional neural network (CANet), and subsequently perform a traditional 
machine learning method to select features, and finally apply a linear regression method 
for overall survival prediction. Third, in the framework, all sub-tasks are intercorrelated 
via the proposed deep learning methods, rather than studied independently. 
Finally, though new WHO tumor classification criteria indicate the use of both 
pathology images and proteomics information along with MRI, the proposed method is 
effective in tumor classification using structural MRI data only. The proposed tumor 
classification results in this work is ranked second place in the testing phase of the 2019 
CPM-RadPath global challenge among 86 registered teams.   
 5.6 Discussion 
Deep learning-based methods have been widely applied to many fields, and have 
achieved start-of-the-art performance. However, brain tumor segmentation poses several 
unique challenges. First, image quality has a critical impact on segmentation 
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performance. For example, blurred images result in poor outcomes. Second, image pre-
processing steps also have an impact on the performance. For example, intensity 
normalization across cases is critical for tumor segmentation. Third, tumor tissue 
heterogeneity may pose a serious challenge to the developing an effective method. 
Finally, data imbalance is common and poses another intricate challenge for the use of 
deep learning. Figure 26 shows the data distribution in the training phase for tumor 
classification and overall survival prediction in our experiments. Cases of glioblastoma 
make up more than 50% of the training data. In survival prediction, range of survival 
days for mid-term survival is too narrow compared to the short- and long-term ranges, 
creating a data imbalance. This data imbalance can result in misclassification. In 
segmentation step, samples for edema is generally much more than other abnormal 
tissues. In order to address the potential data imbalance problem in tumor segmentation, 
Figure 26. Data distribution of training data for tumor classification and overall 
survival prediction. (left) Frequency counts of cases for different classes of tumor. 
(right) Distribution of survival days for short-term (<10 months), mid-term (between 
10-15 months), and long-term (>15 months) categories. 
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we implement tumor segmentation based on MRI sub-regions, rather than using each 
abnormal tissue individually.  
For tumor classification, the main issue is lack of data. In this work, even though we 
increase training sample size using data augmentation techniques, 221 cases may still be 
insufficient number for deep learning. Similar data shortage issue also exists in overall 
survival prediction. There are only 210 cases available in training phase for the CPM-
RadPath 2019 Challenge.  
In addition to the deep learning-based approach, we also implement overall survival 
prediction using a conventional machine learning method by extracting features, such as, 
gray-level co-occurrence matrix (GLCM), intensity, etc., then applying LASSO to select 
features, and finally using linear regression for survival prediction. We compare the result 
with that of our proposed method. The comparison shows that the proposed method 
achieves better performance (as shown in Table 17). 
Table 17. Performance comparison of overall survival prediction using different methods 
on BraTS 2019 validation dataset. 
Method Accuracy MSE medianSE stdSE SpearmanR 
Machine 
learning 0.483 128594 20898 233919 0.044 
The 
proposed 
method 0.586 79146 24362 113801 0.502 
 
We also analyze the impact of gender and age on overall survival in this work. In the 
training data, patients with high-grade glioma (HGG) have 461.0314 average survival 
(AS) days, and 376 median survival (MS) days. Low-grade glioma (LGG) patients have 
1199.8 AS with 814 MS. We investigate impact of average age (AA), median age (MA), 
and gender information to average survival (AS) and median survival (MS), then 
   
 
83 
compare the overall performance. The comparison results are shown in Table 18. For 
patients with HGG, both male and female have similar average and median age (mean 
age difference is less than 1 year), but males have much more AS days (520.6 versus 
433), as well as MS days (426.5 versus 291). However, female patients with LGG (about 
3 years younger) have longer AS period and MS period. Overall, regardless of tumor 
grade, male patients that are older have fewer survival days as shown in our experimental 
data. 
Table 18. Age and survival days comparison based on gender. 
We also conduct statistical analysis on the impact of gender and age to overall 
survival using analysis of variance (ANOVA). The p-value is shown in Table 19. The 
statistical analysis suggests that gender and age are not significant for overall survival for 
this dataset with only 106 patients. 
Table 19. P-value using ANOVA. 





In this Chapter, we investigate multiple tasks in brain tumor analysis by applying 
deep learning-based methods to structural multimodal MRI (mMRI) images. These brain 
tumor analysis tasks consist of tumor segmentation, tumor classification, and overall 
survival prediction. We propose a context-aware deep learning method for tumor 
segmentation since the context encoding module captures global context encoding 
  
HGG LGG Overall 
Case AA MA AS MS Case AA MA AS MS Case AA MA AS MS 
Male 58 60.9 60.6 520.6 426.5 7 51.7 53.8 1188.6 788 65 59.9 59.3 592.6 448 
Female 31 59.3 61.5 433.1 291 10 48.1 50.1 1207.7 983 41 56.6 57.6 622 370 
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features. The segmented tumor is then used for tumor classification by utilizing a 3D 
CNN. Moreover, we also propose a hybrid method for overall survival prediction. 
Specifically, we obtain high-dimensional feature extraction using front-end of the CANet, 
then apply the least absolute shrinkage and selection operator (LASSO) feature selection 
method to these extracted features, and finally implement an overall survival prediction 







































CONCLUSIONS AND FUTURE WORKS 
6.1 Conclusion 
The overall goal of this dissertation is to obtain improved longitudinal brain tumor 
segmentation, tracking, tumor grading, and patient survival prediction. The first goal of 
the dissertation is to improve longitudinal brain tracking. We propose two novel methods: 
feature fusion-based and joint label fusion-based. The feature fusion-based method offers 
improved texture-based brain tumor segmentation in longitudinal mMRI by fusing the 
tumor cell density patterns obtained from biophysical tumor growth modeling with the 
stochastic texture features in a RF-based segmentation method. Statistical analysis shows 
significant performance improvement for the proposed feature fusion method for the 
areas of TC and ET. The JLF-based method fuses results obtained from RF with those 
from GB and helps to improve GB, a state-of-the-art method on longitudinal brain tumor 
segmentation.  
Longitudinal brain tumor tracking not only offers tumor segmentation at current 
stage, but also shows how the tumor changes over time. This may facilitate clinical 
decision making, including treatment management and patient follow-up. 
The second dissertation goal is to build a deep learning-based method for brain tumor 
type and subtype grading, using both pathology and proteomics data, following the new 
2016 WHO tumor classification criteria. The classification method integrates a cellularity 
feature which is derived from the morphology of histologic images to improve 
classification performance. The experiments show that, while the type of DNN may not 
be critical in the discrimination of low-grade from high-grade glioma, DNN may have a 
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significant impact in discriminating Grade II versus Grade III. Moreover, we investigate 
the impact of proteomics and cellularity information on glioma grading. An interesting 
finding of this work is that the cellularity features show promise in prediction of a 
subtype of LGG grade III with IDH mutation. Specifically, for patients with LGG Grade 
III, cellularity of Wild-type IDH is higher than that of Mutant type, suggesting that the 
cellularity feature obtained from a pathology image may be used to classify the more 
aggressive Wild-type IDH subtype of LGG Grade III that has the proteomics 
histopathology of Grade IV.  
An accurate tumor grade combining the phenotype and proteomics information, 
following the latest standard of WHO tumor classification, provides a reliable diagnosis 
and assessment of a brain tumor. This may help healthcare professionals to make good 
treatment planning decisions.  
The final dissertation goal is to propose a universal deep learning model for brain 
tumor segmentation, tumor subtype classification, and overall patient survival prediction. 
We propose a context-aware deep learning method for tumor segmentation, since the 
context encoding module captures global context encoding features. The segmented 
tumor is then used for tumor classification by utilizing a 3D CNN. Moreover, we also 
propose a hybrid method for overall survival prediction. Specifically, we obtain high-
dimensional feature extraction, using the front-end of the CANet, and then we apply the 
least absolute shrinkage and selection operator (LASSO) feature selection method to 
these extracted features, and finally we implement an overall survival prediction method 
based on the selected features.  
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Brain tumor segmentation, tumor subtype classification, and overall patient survival 
prediction are of importance for brain tumor analysis. With the capability of a deep 
neural network, these brain tumor analysis steps are becoming more robust, which may 
help the clinical outcomes for patients with a brain tumor.  
The overall goals, novel contributions, and outcomes of this dissertation are 
summarized in Table 20. 
Table 20. Summary of novel contributions  
Chapter Topic Contributions Results Publications 
3 A longitudinal 
brain tumor 
tracking using 
feature and label 
fusion 
• Exploited tumor 
cell density as a 
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5 A context-aware 
deep learning 







• Proposed a 
context-aware 
deep learning-
based method for 
brain tumor 
segmentation 




• Proposed a tumor 
classification 
using structural 
MRI data only  
The proposed 



























6.2 Future Works 
Even though our proposed work either exceeds and/or reaches state-of-the-art 
performance in the proposed goals, there is a lot of space for improvement. For the first 
dissertation goal, we propose two methods for longitudinal brain tumor tracking, and the 
performance of the experiment shows the state-of-the-art. To make the proposed 
framework even more useful, we plan to extend the models for segmentation of other 
abnormal tissues, such as the cysts and necrosis associated with brain tumor. A more 
robust label fusion may help, for the second method to obtain improved longitudinal 
tumor segmentation prediction. We further plan to improve the underlying feature 
extraction, tumor growth, and segmentation models. A more comprehensive tumor 
growth model development that also considers the treatment modalities may be 
interesting. 
For the second dissertation goal, we propose a deep learning-based method for tumor 
grading by following the new WHO criterion. The experimental results show the 
promising performance. However, this still has challenges. First, development of an 
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automated method may be needed, since region of interest (ROI) selection from the WSI 
is critical for the tasks. Second, we plan to repeat the proposed method and the 
experiments using larger patient data, in order to validate the findings in this study for 
improved tumor type and subtype classification. 
For the final dissertation goal, we propose a deep learning-based method for multiple 
tumor analysis tasks. These tasks are studied together, considering the underlying 
relationship. Although the performances are good, especially for tumor segmentation and 
tumor subtype classification, the performance on overall survival prediction is unstable, 
due to the small number of cases in training. Therefore, we plan to increase the number of 
patient cases to improve the performance. Furthermore, we will integrate the whole slide 
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APPENDIX B: AVERAGE FALSE NEGATIVE RATE (FNR) AND FALSE 
POSITIVE RATE (FPR) COMPARISON BETWEEN RESULT OF THE 
PROPOSED METHOD AND BRATUMIA (BTIA) 
Tumor type WT TC EN 
 JLF BTIA JLF BTIA JLF BTIA 
FNR 0.227 0.3426 0.2489 0.3833 0.1159 0.2698 
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